DK1068241T3 - Antistofvarianter og fragmenter deraf - Google Patents

Antistofvarianter og fragmenter deraf

Info

Publication number: DK1068241T3
Authority: DK; Denmark
Prior art keywords: variant; region; human igg; fragments; amino acid
Prior art date: 1998-04-02

Application number

DK99915101T

Other languages

English (en)

Inventor

Esohe Ekinaduese Idusogie

Michael George Mulkerrin

Leonard G Presta

Robert Laird Shields

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-02

Filing date

1999-03-31

Publication date

2008-02-04

1998-04-02 Priority claimed from US09/054,255 external-priority patent/US6242195B1/en

1999-03-31 Application filed by Genentech Inc filed Critical Genentech Inc

2008-02-04 Application granted granted Critical

2008-02-04 Publication of DK1068241T3 publication Critical patent/DK1068241T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK99915101T 1998-04-02 1999-03-31 Antistofvarianter og fragmenter deraf DK1068241T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/054,255 US6242195B1 (en)	1998-04-02	1998-04-02	Methods for determining binding of an analyte to a receptor
US11610099P	1999-01-15	1999-01-15
PCT/US1999/006858 WO1999051642A1 (en)	1998-04-02	1999-03-31	Antibody variants and fragments thereof

Publications (1)

Publication Number	Publication Date
DK1068241T3 true DK1068241T3 (da)	2008-02-04

Family

ID=26732802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99915101T DK1068241T3 (da)	1998-04-02	1999-03-31	Antistofvarianter og fragmenter deraf

Country Status (12)

Country	Link
EP (1)	EP1068241B1 (da)
JP (1)	JP2002510481A (da)
AT (1)	ATE375365T1 (da)
AU (1)	AU3369999A (da)
CA (1)	CA2323757C (da)
CY (1)	CY1107099T1 (da)
DE (1)	DE69937291T2 (da)
DK (1)	DK1068241T3 (da)
ES (2)	ES2532910T3 (da)
IL (1)	IL138608A0 (da)
PT (1)	PT1068241E (da)
WO (1)	WO1999051642A1 (da)

Families Citing this family (1212)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
MX353234B (es) *	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6676927B1 (en)	1999-01-20	2004-01-13	The Rockefeller University	Animal model and methods for its use in the selection of cytotoxic antibodies
EP1176981B1 (en)	1999-05-07	2005-11-30	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
PL357939A1 (en)	2000-04-11	2004-08-09	Genentech, Inc.	Multivalent antibodies and uses therefor
JP2003531149A (ja)	2000-04-13	2003-10-21	ザ・ロツクフエラー・ユニバーシテイ	抗体由来の免疫応答の増強
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en)	2000-12-12	2010-02-09	Medimmune, Llc	Molecules with extended half-lives, compositions and uses thereof
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
AR035779A1 (es)	2001-02-06	2004-07-14	Genetics Inst Llc	Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
DE60224291T2 (de)	2001-08-27	2008-12-11	Genentech, Inc., South San Francisco	System zur antikörperexpression und- synthese
US20110045005A1 (en)	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7662925B2 (en)	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US8946387B2 (en)	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
DK1534335T4 (da)	2002-08-14	2015-10-05	Macrogenics Inc	Fcgammariib-specifikke antistoffer og fremgangsmåder til anvendelse deraf
US7365168B2 (en)	2002-10-15	2008-04-29	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1578447A4 (en)	2002-10-31	2009-06-03	Genentech Inc	METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
RS20100366A (sr)	2002-12-16	2011-04-30	Genentech, Inc.	Varijante imunoglobulina i njihova upotreba
US7960512B2 (en) *	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en)	2003-01-09	2008-04-08	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
KR101092171B1 (ko)	2003-04-09	2011-12-13	제넨테크, 인크.	Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
US9051373B2 (en)	2003-05-02	2015-06-09	Xencor, Inc.	Optimized Fc variants
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
AU2004256042A1 (en)	2003-06-05	2005-01-20	Genentech, Inc.	BlyS antagonists and uses thereof
EP1636266A2 (en)	2003-06-11	2006-03-22	Wyeth a Corporation of the State of Delaware	Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
EP2292264A3 (en)	2003-07-24	2012-12-19	Innate Pharma	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP2502935B1 (en)	2003-08-22	2017-03-29	Biogen MA Inc.	Improved antibodies having altered effector function and methods for making the same
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8101720B2 (en)	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
JP2007531707A (ja)	2003-10-15	2007-11-08	ピーディーエルバイオファーマ，インコーポレイテッド	ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
EP2385069A3 (en)	2003-11-12	2012-05-30	Biogen Idec MA Inc.	Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
JP2008504007A (ja)	2003-12-19	2008-02-14	ジェネンテック・インコーポレーテッド	治療薬として有用な一価抗体断片
DE602005018325D1 (de)	2004-02-19	2010-01-28	Genentech Inc	Antikörper mit korrigierten cdr
EP2053062A1 (en)	2004-03-24	2009-04-29	Xencor, Inc.	Immunoglobin variants outside the Fc region
BRPI0510915A (pt)	2004-06-04	2007-11-13	Genentech Inc	método para o tratamento da esclerose múltipla e artigo manufaturado
MX2007000404A (es) *	2004-07-12	2008-03-04	Macrogenics Inc	Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
DK2471813T3 (da) *	2004-07-15	2015-03-02	Xencor Inc	Optimerede Fc-varianter
JP5102028B2 (ja)	2004-07-26	2012-12-19	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗ｃｄ１５４抗体
PL2213683T3 (pl)	2004-08-04	2013-10-31	Mentrik Biotech Llc	WARIANTY REGIONÓW Fc
US7476724B2 (en)	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
DK2322556T3 (da)	2004-09-03	2016-01-25	Genentech Inc	Humaniserede anti-beta7-antagonister og anvendelser herfor
CN101087807A (zh)	2004-10-05	2007-12-12	健泰科生物技术公司	治疗血管炎的方法
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
KR20070094890A (ko) *	2004-10-25	2007-09-27	머크 앤드 캄파니 인코포레이티드	안티 ａｄｄｌ 항체 및 그 용도
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
DK1817340T3 (da)	2004-11-12	2012-08-13	Xencor Inc	Fc-varianter med ændret binding til fcrn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
PL1846030T3 (pl)	2005-01-21	2019-05-31	Genentech Inc	Ustalone dawkowanie przeciwciał her
PL1853718T3 (pl)	2005-02-15	2016-01-29	Univ Duke	Przeciwciała anty-CD19 i zastosowania w onkologii
US20060263357A1 (en)	2005-05-05	2006-11-23	Tedder Thomas F	Anti-CD19 antibody therapy for autoimmune disease
EP3195879A1 (en)	2005-02-23	2017-07-26	Genentech, Inc.	Extending time to disease progression or survival in cancer patients
CA2602663A1 (en) *	2005-03-31	2006-10-05	Xencor, Inc.	Fc variants with optimized properties
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9284375B2 (en)	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
ES2707152T3 (es)	2005-04-15	2019-04-02	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
JP5255435B2 (ja) *	2005-04-26	2013-08-07	メディミューン，エルエルシー	ヒンジドメイン操作による抗体エフェクター機能の調節
AU2006251647A1 (en)	2005-05-20	2006-11-30	Genentech, Inc.	Pretreatment of a biological sample from an autoimmune disease subject
CN101267836A (zh)	2005-07-25	2008-09-17	特鲁比昂药品公司	单剂量cd20特异性结合分子的用途
UA97469C2 (uk)	2005-07-25	2012-02-27	Емерджент Продакт Дівелопмент Сіетл, Елелсі	Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
PL1919503T3 (pl)	2005-08-10	2015-04-30	Macrogenics Inc	Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
CA2624189A1 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
AU2006302254B2 (en)	2005-10-06	2011-05-26	Xencor, Inc.	Optimized anti-CD30 antibodies
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
WO2007062090A2 (en)	2005-11-23	2007-05-31	Genentech, Inc.	Methods and compositions related to b cell assays
AU2006338198B2 (en)	2005-12-02	2012-04-26	Genentech, Inc.	Binding polypeptides and uses thereof
EP2623516B1 (en)	2005-12-02	2015-07-15	Genentech, Inc.	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
JP5358187B2 (ja)	2005-12-15	2013-12-04	ジェネンテック，インコーポレイテッド	ポリユビキチンを標的とする方法と組成物
EP1973950B1 (en)	2006-01-05	2014-09-17	Genentech, Inc.	Anti-ephb4 antibodies and methods using the same
NZ599035A (en)	2006-01-12	2013-12-20	Alexion Pharma Inc	Antibodies to ox-2/cd200 and uses thereof
AR059096A1 (es)	2006-01-20	2008-03-12	Genentech Inc	Anticuerpos anti- efrina -b2 y metodos que usan estos
EP1999148B8 (en)	2006-03-06	2014-03-05	Medlmmune, LLC	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
US20090220504A1 (en)	2006-03-21	2009-09-03	Anan Chuntharapai	Combinatorial therapy
DK3056568T3 (da)	2006-03-31	2021-11-01	Chugai Pharmaceutical Co Ltd	Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
US7695928B2 (en)	2006-04-10	2010-04-13	Genentech, Inc.	Disheveled PDZ modulators
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
BRPI0711249A2 (pt)	2006-05-30	2012-03-13	Genentech, Inc.	Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
KR20090027227A (ko)	2006-06-06	2009-03-16	제넨테크, 인크.	항-ｄｌｌ4 항체 및 이의 사용 방법
MX363905B (es)	2006-06-12	2019-04-08	Aptevo Res & Development Llc	Proteinas de union multivalentes monocatenarias con funcion efectora.
JP5764290B2 (ja)	2006-06-26	2015-08-19	マクロジェニクス，インコーポレーテッド	ＦｃγＲＩＩＢ特異的抗体およびその使用法
WO2008002933A2 (en)	2006-06-26	2008-01-03	Macrogenics, Inc.	Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
JP2009543579A (ja)	2006-07-19	2009-12-10	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
ME01786B (me)	2006-08-14	2014-09-20	Xencor Inc	Optimizovana antitela usmerena na cd19
EP2845912A1 (en)	2006-09-12	2015-03-11	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
AU2007299843B2 (en)	2006-09-18	2012-03-08	Xencor, Inc	Optimized antibodies that target HM1.24
ES2636089T3 (es)	2006-10-27	2017-10-05	Genentech, Inc.	Anticuerpos e inmunoconjugados y usos para los mismos
DK2087001T3 (da)	2006-11-02	2017-02-06	Acceleron Pharma Inc	Alk1-receptor- og ligandantagonister og anvendelser deraf
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008100805A2 (en)	2007-02-09	2008-08-21	Genentech, Inc.	Anti-robo4 antibodies and uses therefor
WO2008109440A2 (en)	2007-03-02	2008-09-12	Genentech, Inc.	Predicting response to a her dimerisation inhibitor based on low her3 expression
BRPI0809042B1 (pt)	2007-03-22	2021-08-31	Biogen Ma Inc.	Proteína de ligação a cd154 isolada, seu uso, e composição
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
SI2155248T1 (sl)	2007-04-12	2015-12-31	The Brigham And Women's Hospital, Inc.	Ciljanje ABCB5 za zdravljenje raka
TWI570135B (zh)	2007-04-27	2017-02-11	建南德克公司	高效、穩定且非免疫抑制之抗－ｃｄ４抗體
KR20100017514A (ko)	2007-05-07	2010-02-16	메디뮨 엘엘씨	항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
SG10202000728UA (en)	2007-05-14	2020-03-30	Astrazeneca Ab	Methods of reducing eosinophil levels
EP2173381B1 (en)	2007-05-14	2013-10-02	NovImmune SA	Fc receptor-binding polypeptides with modified effector functions
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP2592156B1 (en)	2007-06-08	2016-04-20	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2188302B1 (en)	2007-07-09	2017-11-01	Genentech, Inc.	Prevention of disulfide bond reduction during recombinant production of polypeptides
CN111499748A (zh)	2007-07-16	2020-08-07	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
NZ583318A (en)	2007-07-16	2012-07-27	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20090499A1 (es)	2007-08-09	2009-05-18	Boehringer Ingelheim Int	Anticuerpos anti-cd37
JP5749009B2 (ja)	2007-08-13	2015-07-15	バスジーンセラピューティクス, インコーポレイテッドVasgenetherapeutics, Inc.	ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
KR102467302B1 (ko)	2007-09-26	2022-11-14	추가이 세이야쿠 가부시키가이샤	항체 정상영역 개변체
EP3689912A1 (en)	2007-09-26	2020-08-05	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PL2233149T3 (pl)	2007-10-16	2016-08-31	Zymogenetics Inc	Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
AU2008323770B2 (en)	2007-11-07	2014-08-07	Genentech, Inc.	Compositions and methods for treatment of microbial disorders
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8795667B2 (en)	2007-12-19	2014-08-05	Macrogenics, Inc.	Compositions for the prevention and treatment of smallpox
AU2008339576B2 (en)	2007-12-21	2014-05-22	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
EP2235059B1 (en)	2007-12-26	2015-02-18	Xencor, Inc.	Fc variants with altered binding to fcrn
EP2077281A1 (en)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2587392T3 (es)	2008-01-31	2016-10-24	Genentech, Inc.	Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
CN102046655B (zh)	2008-04-02	2016-09-14	宏观基因有限公司	Bcr-复合体-特异性抗体和其使用方法
CN107236044B (zh)	2008-04-02	2021-07-02	宏观基因有限公司	HER2/neu-特异性抗体和其使用方法
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
NZ621443A (en)	2008-04-11	2015-09-25	Emergent Product Dev Seattle	Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
KR20200079567A (ko)	2008-05-02	2020-07-03	악셀레론 파마 인코포레이티드	혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
WO2010009271A2 (en)	2008-07-15	2010-01-21	Academia Sinica	Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US9182406B2 (en)	2008-08-04	2015-11-10	Biodesy, Inc.	Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
TW201438738A (zh)	2008-09-16	2014-10-16	建南德克公司	治療進展型多發性硬化症之方法
US20100098730A1 (en)	2008-10-14	2010-04-22	Lowman Henry B	Immunoglobulin variants and uses thereof
US20110293605A1 (en)	2008-11-12	2011-12-01	Hasige Sathish	Antibody formulation
SI2361085T2 (sl)	2008-11-22	2018-11-30	F. Hoffmann-La Roche Ag	Uporaba protitelesa proti vegf v kombinaciji s kemoterapijo za zdravljenje raka dojk
BRPI0917592B1 (pt)	2008-12-09	2021-08-17	Genentech, Inc	Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
WO2010068722A1 (en)	2008-12-12	2010-06-17	Medimmune, Llc	Crystals and structure of a human igg fc variant with enhanced fcrn binding
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
KR101812811B1 (ko)	2008-12-23	2017-12-27	제넨테크, 인크.	단백질 ａ에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
CN102341411A (zh)	2008-12-31	2012-02-01	比奥根艾迪克Ma公司	抗-淋巴细胞毒素抗体
EP2233500A1 (en) *	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
AR075896A1 (es)	2009-03-20	2011-05-04	Genentech Inc	Anticuerpos anti-her (factor de crecimiento epidermico)
HRP20150965T1 (hr)	2009-03-25	2015-11-06	Genentech, Inc.	Anti-fgr3 protutijela i metode koje ih koriste
MY173526A (en)	2009-03-25	2020-01-31	Genentech Inc	Novel anti-?5?1 antibodies and uses thereof
SG174992A1 (en)	2009-04-01	2011-11-28	Genentech Inc	Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2417156B1 (en)	2009-04-07	2015-02-11	Roche Glycart AG	Trivalent, bispecific antibodies
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
JP6095367B2 (ja)	2009-07-13	2017-03-15	ジェネンテック，インコーポレイテッド	癌治療のための診断方法および組成物
TW201106972A (en)	2009-07-27	2011-03-01	Genentech Inc	Combination treatments
JP2013500993A (ja)	2009-07-31	2013-01-10	ジェネンテック，インコーポレイテッド	Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
MX355650B (es)	2009-08-11	2018-04-26	Genentech Inc	Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011020049A1 (en)	2009-08-14	2011-02-17	Genentech, Inc.	Biological markers for monitoring patient response to vegf antagonists
WO2011022264A1 (en)	2009-08-15	2011-02-24	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EP3222287A1 (en)	2009-08-24	2017-09-27	Amunix Operating Inc.	Coagulation factor ix compositions and methods of making and using same
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3211094A3 (en)	2009-09-03	2017-11-01	F. Hoffmann-La Roche AG	Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US20110064670A1 (en)	2009-09-11	2011-03-17	Genentech, Inc.	Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
AU2010296018B2 (en)	2009-09-16	2016-05-05	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
MX2012002909A (es)	2009-09-17	2012-04-19	Hoffmann La Roche	Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
AU2010303415B2 (en)	2009-10-07	2015-02-19	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP2010004895A (ja) *	2009-10-13	2010-01-14	Hiroshima Univ	ヒト化ニワトリ抗体の製造方法
TW201119677A (en)	2009-10-19	2011-06-16	Genentech Inc	Modulators of hepatocyte growth factor activator
MX2012004647A (es)	2009-10-22	2012-06-19	Genentech Inc	Anticuerpos antihepsina y metodos para su uso.
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
EP2493922B1 (en)	2009-10-26	2017-02-15	F. Hoffmann-La Roche AG	Method for the production of a glycosylated immunoglobulin
SG10201912571XA (en)	2009-11-02	2020-02-27	Univ Washington	Therapeutic nuclease compositions and methods
CA2780143A1 (en)	2009-11-05	2011-05-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
IN2012DN05169A (da)	2009-12-02	2015-10-23	Acceleron Pharma Inc
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
JP5989544B2 (ja)	2009-12-09	2016-09-07	バイエル・ファルマ・アクティエンゲゼルシャフト	抗Ｃ４．４ａ抗体およびその使用
WO2011071577A1 (en)	2009-12-11	2011-06-16	Genentech, Inc.	Anti-vegf-c antibodies and methods using same
AU2010336485B2 (en)	2009-12-23	2015-03-26	Genentech, Inc.	Anti-Bv8 antibodies and uses thereof
SG182408A1 (en)	2010-01-11	2012-08-30	Alexion Pharma Inc	Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011091078A2 (en)	2010-01-19	2011-07-28	Xencor, Inc.	Antibody fc variants with enhanced complement activity
MX341687B (es)	2010-02-10	2016-08-30	Immunogen Inc	"anticuerpos cd20 y su utilización".
CA2784211C (en)	2010-02-18	2019-12-24	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
RU2012140447A (ru)	2010-02-23	2014-03-27	Дженентек, Инк.	Антиангиогенная терапия для лечения рака яичника
LT2542256T (lt)	2010-03-04	2019-10-25	Macrogenics Inc	Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012022044A2 (pt)	2010-03-24	2020-08-25	Genentech Inc	''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
PT2563813E (pt)	2010-04-30	2015-11-26	Alexion Pharma Inc	Anticorpos anti-c5a e métodos para utilização dos anticorpos
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
WO2011153224A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
SG185430A1 (en)	2010-06-03	2012-12-28	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
CA2794731C (en)	2010-06-18	2019-03-19	Genentech, Inc.	Anti-axl antibodies and methods of use
CA2803588A1 (en)	2010-06-22	2011-12-29	The Regents Of The University Of Colorado, A Body Corporate	Antibodies to the c3d fragment of complement component 3
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
TW201217527A (en)	2010-07-09	2012-05-01	Biogen Idec Hemophilia Inc	Processable single chain molecules and polypeptides made using same
CN103097418A (zh)	2010-07-09	2013-05-08	霍夫曼-拉罗奇有限公司	抗神经毡蛋白抗体及使用方法
EP2409989A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Method to improve glycosylation profile for antibody
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
EP2596026B1 (en)	2010-07-23	2020-04-08	Trustees of Boston University	Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
ES2667100T3 (es)	2010-08-02	2018-05-09	Macrogenics, Inc.	Diacuerpos covalentes y sus usos
WO2012018771A1 (en)	2010-08-03	2012-02-09	Genentech, Inc.	Chronic lymphocytic leukemia (cll) biomarkers
BR112013002532A2 (pt)	2010-08-05	2016-05-31	Hoffmann La Roche	proteína de fusão de citocina anti-viral do anticorpo anti-mhc
MX2013001336A (es)	2010-08-13	2013-03-08	Roche Glycart Ag	Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
NZ703653A (en)	2010-08-13	2016-09-30	Roche Glycart Ag	Anti-fap antibodies and methods of use
TW201215405A (en)	2010-08-25	2012-04-16	Hoffmann La Roche	Antibodies against IL-18R1 and uses thereof
RU2013114360A (ru)	2010-08-31	2014-10-10	Дженентек, Инк.	Биомаркеры и способы лечения
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
KR20220070586A (ko)	2010-11-08	2022-05-31	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
CA2815840A1 (en)	2010-11-10	2012-05-18	Genentech, Inc.	Methods and compositions for neural disease immunotherapy
FI3434767T3 (fi)	2010-11-30	2026-02-12	Chugai Seiyaku Kk	Sytotoksisuutta aiheuttava terapeuttinen aine
WO2012075037A1 (en)	2010-11-30	2012-06-07	Genentech, Inc.	Low affinity blood brain barrier receptor antibodies and uses therefor
TWI761912B (zh)	2010-11-30	2022-04-21	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
TWI708944B (zh)	2010-12-16	2020-11-01	美商建南德克公司	關於th2抑制作用之診斷及治療
AU2011349443B2 (en)	2010-12-20	2015-12-24	Genentech, Inc.	Anti-mesothelin antibodies and immunoconjugates
PH12013501339A1 (en)	2010-12-22	2013-08-28	Genentech Inc	Anti-pcsk9 antibodies and methods of use
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
CA2826453A1 (en)	2011-02-03	2012-08-09	Alexion Pharmaceuticals, Inc.	Use of an anti-cd200 antibody for prolonging the survival of allografts
MX340671B (es)	2011-02-10	2016-07-20	Roche Glycart Ag	Polipeptidos interleuquina- 2 mutantes.
RU2013141078A (ru)	2011-02-28	2015-04-10	Ф. Хоффманн-Ля Рош Аг	Одновалентные антигенсвязывающие белки
JP6271254B2 (ja)	2011-02-28	2018-01-31	ジェネンテック，インコーポレイテッド	Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法
MX341921B (es)	2011-02-28	2016-09-07	Hoffmann La Roche	Proteinas de union a antigeno.
CA2831136A1 (en)	2011-03-21	2012-09-27	Biodesy, Llc	Classification of kinase inhibitors using nonlinear optical techniques
TR201815420T4 (tr)	2011-03-29	2018-11-21	Roche Glycart Ag	Antikor fc varyantları.
BR112013024717A2 (pt)	2011-04-07	2017-08-08	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
US9469676B2 (en)	2011-04-13	2016-10-18	Bristol-Myers Squibb Company	Fc fusion proteins comprising novel linkers or arrangements
CN108341863A (zh)	2011-04-20	2018-07-31	阿塞勒隆制药公司	内皮糖蛋白多肽及其用途
WO2012145493A1 (en)	2011-04-20	2012-10-26	Amplimmune, Inc.	Antibodies and other molecules that bind b7-h1 and pd-1
PH12013502441B1 (en)	2011-04-29	2019-02-08	Univ Washington	Therapeutic nuclease compositions and methods
WO2012146630A1 (en)	2011-04-29	2012-11-01	F. Hoffmann-La Roche Ag	N-terminal acylated polypeptides, methods for their production and uses thereof
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR101992502B1 (ko)	2011-05-12	2019-06-24	제넨테크, 인크.	프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
PH12013502294A1 (en)	2011-05-16	2014-01-27	Genentech Inc	Fgfr1 agonists and methods of use
EP2710032B1 (en)	2011-05-20	2019-12-25	Momenta Pharmaceuticals, Inc.	Modified glycoproteins
JP6145088B2 (ja)	2011-05-21	2017-06-07	マクロジェニクス，インコーポレーテッド	脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
WO2012170969A2 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
EP2721067B1 (en)	2011-06-15	2019-07-31	F.Hoffmann-La Roche Ag	Anti-human epo receptor antibodies and methods of use
AR086982A1 (es)	2011-06-22	2014-02-05	Hoffmann La Roche	Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
US20130004484A1 (en)	2011-06-30	2013-01-03	Genentech, Inc.	Anti-c-met antibody formulations
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR20200120743A (ko) *	2011-07-06	2020-10-21	젠맵 비. 브이	항체 변이체 및 그의 용도
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AU2012296613B2 (en)	2011-08-15	2016-05-12	Amplimmune, Inc.	Anti-B7-H4 antibodies and their uses
CN103890007A (zh)	2011-08-17	2014-06-25	霍夫曼-拉罗奇有限公司	神经调节蛋白抗体及其用途
KR20140068877A (ko)	2011-08-17	2014-06-09	제넨테크, 인크.	불응성 종양에서의 혈관신생의 억제
MX2014002053A (es)	2011-08-23	2014-04-25	Roche Glycart Ag	Anticuerpos anti -mcsp y metodos de uso.
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
US20130108641A1 (en)	2011-09-14	2013-05-02	Sanofi	Anti-gitr antibodies
BR112014005720A2 (pt)	2011-09-15	2017-12-12	Genentech Inc	método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
AR087918A1 (es)	2011-09-19	2014-04-23	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
CN107098967A (zh)	2011-09-30	2017-08-29	达纳-法伯癌症研究所股份有限公司	治疗肽
BR112014008212A2 (pt)	2011-10-05	2017-06-13	Genentech Inc	método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
KR102102862B1 (ko)	2011-10-14	2020-04-22	제넨테크, 인크.	항-HtrA1 항체 및 사용 방법
EP2766034B1 (en)	2011-10-14	2018-06-13	F. Hoffmann-La Roche AG	Zymogen activators
US9358250B2 (en)	2011-10-15	2016-06-07	Genentech, Inc.	Methods of using SCD1 antagonists
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
AU2012328980A1 (en)	2011-10-28	2014-04-24	Genentech, Inc.	Therapeutic combinations and methods of treating melanoma
CN104066748A (zh)	2011-11-21	2014-09-24	霍夫曼-拉罗奇有限公司	抗c-met抗体的纯化
RU2014124530A (ru)	2011-11-23	2015-12-27	Идженика, Инк.	Антитела к cd98 и способы их применения
AR088941A1 (es)	2011-11-23	2014-07-16	Bayer Ip Gmbh	Anticuerpos anti-fgfr2 y sus usos
CN104105708B (zh)	2011-12-05	2018-04-03	X博迪生物科学公司	PDGF受体β结合多肽
EP2788024A1 (en)	2011-12-06	2014-10-15	F.Hoffmann-La Roche Ag	Antibody formulation
WO2013101509A2 (en)	2011-12-15	2013-07-04	Alternative Innovative Technologies Llc	Hsp70 fusion protein conjugates and uses thereof
AR089434A1 (es)	2011-12-23	2014-08-20	Genentech Inc	Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
CN104411717A (zh)	2012-01-09	2015-03-11	斯克利普斯研究所	具有超长cdr3s的人源化抗体
CN111499760A (zh)	2012-01-12	2020-08-07	比奥贝拉蒂治疗公司	嵌合因子viii多肽及其用途
CA2862835A1 (en)	2012-01-13	2013-07-18	Genentech, Inc.	Biological markers for identifying patients for treatment with vegf antagonists
EP2804629A1 (en)	2012-01-18	2014-11-26	Genentech, Inc.	Anti-lrp5 antibodies and methods of use
KR20140119114A (ko)	2012-01-18	2014-10-08	제넨테크, 인크.	Fgf19 조절제의 사용 방법
TW201334789A (zh)	2012-01-31	2013-09-01	Genentech Inc	抗ｉｇｅ抗體及其使用方法
MX366804B (es)	2012-02-11	2019-07-25	Genentech Inc	Translocaciones de la r-espondina y sus metodos de uso.
ES2771208T3 (es)	2012-02-15	2020-07-06	Bioverativ Therapeutics Inc	Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2814587B1 (en)	2012-02-15	2018-05-02	F.Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
DK2822577T3 (da)	2012-02-15	2019-04-01	Bioverativ Therapeutics Inc	Rekombinante faktor viii-proteiner
US9139863B2 (en)	2012-03-16	2015-09-22	Genentech, Inc.	Engineered conformationally-stabilized proteins
CA2866835A1 (en)	2012-03-16	2013-09-19	Genentech, Inc.	Engineered conformationally-stabilized proteins
JP2015514710A (ja)	2012-03-27	2015-05-21	ジェネンテック，インコーポレイテッド	Ｈｅｒ３阻害剤に関する診断及び治療
EP3246339B1 (en)	2012-03-28	2019-10-09	Sanofi	Antibodies to bradykinin b1 receptor ligands
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US20150056190A1 (en)	2012-03-30	2015-02-26	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
AU2013243861A1 (en)	2012-04-05	2014-10-23	Ac Immune S.A.	Humanized Tau antibody
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP4234577A3 (en)	2012-04-25	2023-10-18	Momenta Pharmaceuticals, Inc.	Modified glycoproteins
CN106290917B (zh)	2012-04-25	2020-06-05	比奥德赛公司	用于检测蛋白质的变构调节剂的方法
KR20150006000A (ko)	2012-05-01	2015-01-15	제넨테크, 인크.	항-pmel17 항체 및 면역접합체
MX2014013637A (es)	2012-05-07	2015-02-05	Sanofi Sa	Metodos para prevencion de la formacion de biopelicula.
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
ES2682761T3 (es)	2012-05-18	2018-09-21	Genentech, Inc.	Formulaciones de anticuerpos monoclonales de alta concentración
MY181743A (en)	2012-05-21	2021-01-06	Genentech Inc	Methods for improving safety of blood-brain barrier transport
WO2013175276A1 (en)	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
MX2014014086A (es)	2012-05-23	2015-01-26	Genentech Inc	Metodo de seleccion para agentes terapeuticos.
US10202595B2 (en)	2012-06-08	2019-02-12	Bioverativ Therapeutics Inc.	Chimeric clotting factors
CA2875246A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Procoagulant compounds
KR20150023711A (ko)	2012-06-15	2015-03-05	제넨테크, 인크.	항-pcsk9 항체, 제제, 투여, 및 사용 방법
CA2877363A1 (en)	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
RU2684595C2 (ru)	2012-07-04	2019-04-09	Ф.Хоффманн-Ля Рош Аг	Ковалентно связанные конъюгаты антиген-антитело
CA2872192A1 (en)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Anti-biotin antibodies and methods of use
EP3138578B1 (en)	2012-07-04	2022-01-12	F. Hoffmann-La Roche AG	Anti-theophylline antibodies and methods of use
CN110042114B (zh)	2012-07-05	2024-09-10	弗·哈夫曼-拉罗切有限公司	表达和分泌系统
EP2870250B2 (en)	2012-07-06	2022-06-29	Bioverativ Therapeutics Inc.	Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013285355A1 (en)	2012-07-06	2015-01-29	Genmab B.V.	Dimeric protein with triple mutations
EP3632462A1 (en)	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
CN104428007B (zh)	2012-07-09	2018-03-16	基因泰克公司	包含抗cd22抗体的免疫缀合物
US20140030280A1 (en)	2012-07-09	2014-01-30	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates
TW201408697A (zh)	2012-07-09	2014-03-01	Genentech Inc	抗ｃｄ７９ｂ抗體及免疫結合物
EP2684896A1 (en)	2012-07-09	2014-01-15	International-Drug-Development-Biotech	Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
IN2014DN10510A (da)	2012-07-09	2015-08-21	Genentech Inc
SI2882450T1 (sl)	2012-07-11	2020-02-28	Bioverativ Therapeutics Inc.	Kompleks faktorja VIII z XTEN in s proteinom von Willebrandovega faktorja in njegove uporabe
DK3495387T3 (da)	2012-07-13	2021-11-08	Roche Glycart Ag	Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
CN104508132B (zh)	2012-08-02	2017-09-15	弗·哈夫曼-拉罗切有限公司	用于产生作为与惰性免疫球蛋白Fc区Fc融合的可溶FcR的方法及其用途
US9914956B2 (en)	2012-08-18	2018-03-13	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
BR112015001955A2 (pt)	2012-08-24	2017-11-07	Chugai Pharmaceutical Co Ltd	variante de região fc específica de fcgamariib
JP6774164B2 (ja)	2012-08-24	2020-10-21	中外製薬株式会社	マウスＦｃγＲＩＩ特異的Ｆｃ抗体
KR102036262B1 (ko)	2012-08-29	2019-10-24	에프. 호프만-라 로슈 아게	혈액 뇌 장벽 셔틀
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
RS57748B1 (sr)	2012-09-12	2018-12-31	Genzyme Corp	Polipeptidi sa izmenjenom glikozilacijom i smanjenom efektorskom funkcijom koji sadrže fc
CA2887129A1 (en)	2012-10-09	2014-04-17	Igenica, Inc.	Anti-c16orf54 antibodies and methods of use thereof
EP4223770A3 (en)	2012-11-05	2023-10-18	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
HK1214830A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型ntrk1融合分子及其应用
CA2884431A1 (en)	2012-11-08	2014-05-15	F. Hoffmann-La Roche Ag	Her3 antigen binding proteins binding to the beta-hairpin of her3
CA2890669A1 (en)	2012-11-13	2014-05-22	Genetech, Inc.	Anti-hemagglutinin antibodies and methods of use
JP2016509582A (ja)	2012-12-19	2016-03-31	アンプリミューン，インコーポレイテッド	抗ヒトｂ７−ｈ４抗体およびその使用
US9790277B2 (en)	2012-12-21	2017-10-17	The Johns Hopkins University	Anti-H7CR antibodies
KR20150097688A (ko)	2012-12-21	2015-08-26	에프. 호프만-라 로슈 아게	디술피드-연결 다가 ｍｈｃ 클래스 ｉ 포함 다관능 단백질
KR20220156667A (ko)	2013-01-10	2022-11-25	젠맵 비. 브이	인간 IgG1 Fc 영역 변이체 및 그의 용도
AU2014207342C1 (en)	2013-01-18	2019-04-04	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
WO2014126871A1 (en)	2013-02-12	2014-08-21	Bristol-Myers Squibb Company	Tangential flow filtration based protein refolding methods
WO2014126884A1 (en)	2013-02-12	2014-08-21	Bristol-Myers Squibb Company	High ph protein refolding methods
WO2014127215A1 (en)	2013-02-15	2014-08-21	Biogen Idec Ma Inc.	Optimized factor viii gene
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
RU2015140573A (ru)	2013-02-25	2017-03-30	Дженентек, Инк.	Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
WO2014131715A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Anti-mcsp antibodies
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
WO2014164503A1 (en)	2013-03-11	2014-10-09	Genzyme Corporation	Hyperglycosylated binding polypeptides
CN105189552B (zh)	2013-03-14	2019-08-02	基因泰克公司	抗b7-h4抗体和免疫缀合物
LT2968520T (lt)	2013-03-14	2021-09-27	Macrogenics, Inc.	Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
EP2968540A2 (en)	2013-03-14	2016-01-20	Genentech, Inc.	Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
EP2968565A2 (en)	2013-03-14	2016-01-20	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
CN105142668B (zh)	2013-03-15	2018-04-27	达纳-法伯癌症研究院公司	治疗性肽
WO2014151006A2 (en)	2013-03-15	2014-09-25	Genentech, Inc.	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
HK1211963A1 (en)	2013-03-15	2016-06-03	豪夫迈．罗氏有限公司	Compositions and methods for diagnosis and treatment of hepatic cancers
JP6568514B2 (ja)	2013-03-15	2019-08-28	エーシーイミューンエス．エー．	抗タウ抗体及び使用方法
CN105339001A (zh)	2013-03-15	2016-02-17	基因泰克公司	治疗癌症和预防癌症耐药性的方法
SG10201913874TA (en)	2013-03-15	2020-03-30	Biogen Ma Inc	Factor ix polypeptide formulations
CN105143252A (zh)	2013-03-15	2015-12-09	豪夫迈·罗氏有限公司	IL-22多肽和IL-22Fc融合蛋白及其使用方法
JP2016517441A (ja)	2013-03-15	2016-06-16	ジェネンテック，インコーポレイテッド	抗ＣＲＴｈ２抗体及び使用方法
JP6598680B2 (ja)	2013-04-02	2019-10-30	中外製薬株式会社	Ｆｃ領域改変体
WO2014177461A1 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
JP6618893B2 (ja)	2013-04-29	2019-12-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｆｃ受容体結合が変更された非対称抗体および使用方法
PE20151807A1 (es)	2013-04-29	2015-12-02	Hoffmann La Roche	Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
HRP20240107T1 (hr)	2013-05-20	2024-04-12	F. Hoffmann - La Roche Ag	Protutijela na transferinski receptor i postupci uporabe
AU2014268298B2 (en)	2013-05-24	2019-01-17	Medlmmune, Llc	Anti-B7-H5 antibodies and their uses
PE20160716A1 (es)	2013-06-14	2016-08-11	Bayer Pharma AG	Anticuerpo anti-tweakr y sus usos
EP3013365B1 (en)	2013-06-26	2019-06-05	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (en)	2013-07-18	2016-05-25	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
ES2719103T3 (es)	2013-08-01	2019-07-08	Five Prime Therapeutics Inc	Anticuerpos anti-FGFR2IIIB afucosilados
US10947269B2 (en)	2013-08-08	2021-03-16	Bioverativ Therapeutics Inc.	Purification of chimeric FVIII molecules
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
JP6463359B2 (ja)	2013-08-12	2019-01-30	ジェネンテック，インコーポレイテッド	補体関連病態を治療するための組成物及び方法
TW201722994A (zh)	2013-08-13	2017-07-01	賽諾菲公司	胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
SG10201710013RA (en)	2013-08-13	2018-01-30	Sanofi Sa	Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
PL3036320T5 (pl)	2013-08-19	2024-06-10	Biogen Ma Inc.	Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
US20150056199A1 (en)	2013-08-22	2015-02-26	Acceleron Pharma, Inc.	Tgf-beta receptor type ii variants and uses thereof
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CA2923579C (en)	2013-09-06	2023-09-05	Academia Sinica	Human inkt cell activation using glycolipids with altered glycosyl groups
JP2016537399A (ja)	2013-09-17	2016-12-01	ジェネンテック，インコーポレイテッド	抗ｌｇｒ５抗体を使用する方法
US10611794B2 (en)	2013-09-25	2020-04-07	Bioverativ Therapeutics Inc.	On-column viral inactivation methods
US10414818B2 (en)	2013-09-27	2019-09-17	Roche Diagnostics Operations, Inc.	Thermus thermophilus SlyD FKBP domain specific antibodies
CN105814078A (zh)	2013-10-11	2016-07-27	豪夫迈·罗氏有限公司	Nsp4抑制剂及其使用方法
RU2016115866A (ru)	2013-10-11	2017-11-16	Ф. Хоффманн-Ля Рош Аг	Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
MX2016004802A (es)	2013-10-18	2016-07-18	Genentech Inc	Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
AR098155A1 (es)	2013-10-23	2016-05-04	Genentech Inc	Métodos para diagnosticar y tratar trastornos eosinofílicos
AU2014339898B2 (en)	2013-10-25	2020-07-23	Acceleron Pharma, Inc.	Endoglin peptides to treat fibrotic diseases
US10988745B2 (en)	2013-10-31	2021-04-27	Resolve Therapeutics, Llc	Therapeutic nuclease-albumin fusions and methods
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
WO2015070014A1 (en)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Procoagulant fusion compound
RU2718990C1 (ru)	2013-11-21	2020-04-15	Ф. Хоффманн-Ля Рош Аг	Антитела к альфа-синуклеину и способы применения
MX371187B (es)	2013-12-06	2020-01-22	Dana Farber Cancer Inst Inc	Péptidos terapéuticos.
AU2014363944B2 (en)	2013-12-09	2020-03-26	Allakos Inc.	Anti-Siglec-8 antibodies and methods of use thereof
PE20160712A1 (es)	2013-12-13	2016-07-26	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd33
JP2017501167A (ja)	2013-12-17	2017-01-12	ジェネンテック，インコーポレイテッド	Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN112353943A (zh)	2013-12-17	2021-02-12	豪夫迈·罗氏有限公司	用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
HRP20240939T1 (hr)	2013-12-17	2024-10-25	Genentech, Inc.	Anti-cd3 protutijela i metode uporabe
WO2015095410A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
CA2932958A1 (en)	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Humanized anti-tau(ps422) antibodies and methods of use
CN106029697B (zh)	2013-12-20	2021-06-04	英特维特国际股份有限公司	具有经修饰的ch2-ch3序列的犬抗体
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
EP3089759B1 (en)	2014-01-03	2018-12-05	F. Hoffmann-La Roche AG	Covalently linked polypeptide toxin-antibody conjugates
CA2930154A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
WO2015101586A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
JP6557664B2 (ja)	2014-01-06	2019-08-07	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	一価の血液脳関門シャトルモジュール
NZ721544A (en)	2014-01-10	2022-10-28	Bioverativ Therapeutics Inc	Factor viii chimeric proteins and uses thereof
CA2931986A1 (en)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with modified fcrn- and maintained protein a-binding properties
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
JP2017505305A (ja)	2014-01-24	2017-02-16	ジェネンテック，インコーポレイテッド	抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
AU2015209131B2 (en)	2014-01-24	2020-06-25	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
EP3102197B1 (en)	2014-02-04	2018-08-29	Genentech, Inc.	Mutant smoothened and methods of using the same
ES2873248T3 (es)	2014-02-08	2021-11-03	Hoffmann La Roche	Métodos para tratar la enfermedad de Alzheimer
KR20160111039A (ko)	2014-02-08	2016-09-23	제넨테크, 인크.	알츠하이머 질환을 치료하는 방법
TR201810635T4 (tr)	2014-02-12	2018-08-27	Hoffmann La Roche	Anti-jagged1 antikorları ve kullanım yöntemleri.
KR20160124165A (ko)	2014-02-21	2016-10-26	제넨테크, 인크.	항-il-13/il-17 이중특이적 항체 및 그의 용도
DK3110446T3 (da)	2014-02-28	2022-02-28	Allakos Inc	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
BR112016020368A2 (pt)	2014-03-05	2018-01-23	Ucb Biopharma Sprl	proteínas fc multiméricas
NZ711451A (en)	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
EP3116999B1 (en)	2014-03-14	2021-09-15	F. Hoffmann-La Roche AG	Methods and compositions for secretion of heterologous polypeptides
CN106456728A (zh)	2014-03-14	2017-02-22	达纳－法伯癌症研究所公司	恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
CN116333148A (zh)	2014-03-19	2023-06-27	建新公司	靶向模块的位点特异性糖工程化
US20170107294A1 (en)	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
EP3119812B1 (en)	2014-03-21	2020-04-29	X-Body, Inc.	Bi-specific antigen-binding polypeptides
EP3119490B1 (en)	2014-03-21	2021-09-08	F. Hoffmann-La Roche AG	In vitro prediction of in vivo half-life of antibodies
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP6562942B2 (ja)	2014-03-27	2019-08-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	反応性標識化合物およびその使用
CA2943834A1 (en)	2014-03-31	2015-10-08	Genentech, Inc.	Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
CN106103486B (zh)	2014-03-31	2020-04-21	豪夫迈·罗氏有限公司	抗ox40抗体和使用方法
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
SG11201608696RA (en)	2014-05-05	2016-11-29	Regeneron Pharma	Humanized c5 and c3 animals
KR20170003582A (ko)	2014-05-22	2017-01-09	제넨테크, 인크.	항-gpc3 항체 및 면역접합체
JP2017524371A (ja)	2014-05-23	2017-08-31	ジェネンテック，インコーポレイテッド	Ｍｉｔバイオマーカーとその使用方法
DK3149045T3 (da)	2014-05-27	2023-03-06	Academia Sinica	Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20220151036A (ko)	2014-05-27	2022-11-11	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
US10005847B2 (en)	2014-05-27	2018-06-26	Academia Sinica	Anti-HER2 glycoantibodies and uses thereof
AU2015267044A1 (en)	2014-05-28	2016-12-15	Academia Sinica	Anti-TNF-alpha glycoantibodies and uses thereof
SMT201900745T1 (it)	2014-05-30	2020-01-14	Henlix Biotech Co Ltd	Anticopri anti-recettore del fattore di crescita epidermico (egfr)
CA2949982A1 (en)	2014-06-11	2015-12-17	Genentech, Inc.	Anti-lgr5 antibodies and uses thereof
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
EP3164419B1 (en)	2014-06-26	2024-07-24	F. Hoffmann-La Roche AG	Anti-brdu antibodies and methods of use
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP3160478A4 (en)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimized factor ix gene
RU2715038C2 (ru)	2014-07-11	2020-02-21	Дженентек, Инк.	Антитела анти-pd-l1 и способы их диагностического применения
WO2016007775A1 (en)	2014-07-11	2016-01-14	Genentech, Inc.	Notch pathway inhibition
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
AU2015311913B2 (en)	2014-09-03	2019-09-12	Boehringer Ingelheim International Gmbh	Compound targeting IL-23A and TNF-alpha and uses thereof
FR3025515B1 (fr)	2014-09-05	2016-09-09	Lab Francais Du Fractionnement	Procede de purification d'un anticorps monoclonal
WO2016040369A2 (en)	2014-09-08	2016-03-17	Academia Sinica	HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP3567056A1 (en)	2014-09-10	2019-11-13	F. Hoffmann-La Roche AG	Galactoengineered immunoglobulin 1 antibodies
CN107108724A (zh)	2014-09-12	2017-08-29	豪夫迈·罗氏有限公司	半胱氨酸改造抗体和缀合物
CN113698485A (zh)	2014-09-12	2021-11-26	基因泰克公司	抗-b7-h4抗体及免疫缀合物
MX2017003126A (es)	2014-09-12	2017-08-28	Genentech Inc	Anticuerpos anti-her2 e inmunoconjugados.
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
RU2727663C2 (ru)	2014-09-17	2020-07-22	Дженентек, Инк.	Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
RS60349B8 (sr)	2014-09-23	2022-10-31	Hoffmann La Roche	Postupak upotrebe anti-cd79b imunokonjugata
SG11201701803XA (en)	2014-09-26	2017-04-27	Bayer Pharma AG	Stabilized adrenomedullin derivatives and use thereof
MX386297B (es)	2014-09-29	2025-03-18	Univ Duke	Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
DK3201230T3 (da)	2014-09-30	2021-02-15	Intervet Int Bv	Canine pd-l1-bindende pd-l1-antistoffer
AU2015330869B2 (en)	2014-10-09	2021-07-08	Genzyme Corporation	Glycoengineered antibody drug conjugates
CA2964317C (en)	2014-10-14	2021-10-05	Halozyme, Inc.	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP2017536102A (ja)	2014-10-16	2017-12-07	ジェネンテック，インコーポレイテッド	抗アルファ−シヌクレイン抗体及び使用方法
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3223865A4 (en)	2014-10-31	2018-10-03	Jounce Therapeutics, Inc.	Methods of treating conditions with antibodies that bind b7-h4
RU2017119231A (ru)	2014-11-03	2018-12-06	Дженентек, Инк.	Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
KR20170086540A (ko)	2014-11-03	2017-07-26	제넨테크, 인크.	T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
ES2819256T3 (es)	2014-11-05	2021-04-15	Genentech Inc	Métodos para producir proteínas bicatenarias en bacterias
MX2017003478A (es)	2014-11-05	2018-02-01	Genentech Inc	Anticuerpos anti-fgfr2/3 y metodos para su uso.
EP3215526A1 (en)	2014-11-05	2017-09-13	F. Hoffmann-La Roche AG	Methods of producing two chain proteins in bacteria
RU2017119428A (ru)	2014-11-06	2018-12-06	Дженентек, Инк.	Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
PL3215528T3 (pl)	2014-11-06	2020-01-31	F.Hoffmann-La Roche Ag	Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
BR112017006591A2 (pt)	2014-11-06	2018-01-16	Hoffmann La Roche	polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
WO2016077369A1 (en)	2014-11-10	2016-05-19	Genentech, Inc.	Animal model for nephropathy and agents for treating the same
US10093730B2 (en)	2014-11-10	2018-10-09	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP3789403A1 (en)	2014-11-11	2021-03-10	MedImmune Limited	Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
KR20170096112A (ko)	2014-11-17	2017-08-23	제넨테크, 인크.	Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
CN107108745B (zh)	2014-11-19	2021-01-12	基因泰克公司	抗bace1的抗体和其用于神经疾病免疫疗法的用途
SI3221349T1 (sl)	2014-11-19	2021-02-26	Axon Neuroscience Se	Humanizirano tau protitelo pri alzheimerjevi bolezni
WO2016081643A1 (en)	2014-11-19	2016-05-26	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
JP6993228B2 (ja)	2014-11-19	2022-03-03	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
UY36404A (es)	2014-11-21	2016-06-01	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
EP3221346B1 (en)	2014-11-21	2020-09-02	Bristol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
JP6721590B2 (ja)	2014-12-03	2020-07-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体
PL3227336T3 (pl)	2014-12-05	2019-11-29	Hoffmann La Roche	Przeciwciała anty-CD79b i sposoby stosowania
KR20170085595A (ko)	2014-12-10	2017-07-24	제넨테크, 인크.	혈뇌 장벽 수용체 항체 및 사용 방법
BR112017011235A2 (pt)	2014-12-19	2018-02-06	Chugai Pharmaceutical Co Ltd	anticorpos anti-c5 e métodos de uso
EP4600372A3 (en)	2014-12-19	2025-11-19	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
DK3233912T3 (da)	2014-12-19	2021-08-02	Regenesance B V	Antistoffer, der binder human c6, og anvendelser deraf
WO2016106286A1 (en)	2014-12-23	2016-06-30	Biodesy, Inc.	Attachment of proteins to interfaces for use in nonlinear optical detection
US10189902B2 (en)	2014-12-23	2019-01-29	Bristol-Myers Squibb Company	Antibodies to TIGIT
US20160200815A1 (en)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
WO2016117346A1 (en)	2015-01-22	2016-07-28	Chugai Seiyaku Kabushiki Kaisha	A combination of two or more anti-c5 antibodies and methods of use
EP3048116A1 (en)	2015-01-23	2016-07-27	International-Drug-Development-Biotech	Anti-dr5 antibodies with enhanced apoptosis potency
TWI710571B (zh)	2015-01-24	2020-11-21	中央研究院	腫瘤標記及其使用方法
TWI736523B (zh)	2015-01-24	2021-08-21	中央研究院	新穎聚醣結合物及其使用方法
JP2018506275A (ja)	2015-01-28	2018-03-08	ジェネンテック，インコーポレイテッド	多発性硬化症の遺伝子発現マーカー及び治療
HK1244512A1 (zh)	2015-02-04	2018-08-10	健泰科生物技术公司	突变型smoothened及其使用方法
CN114773469B (zh)	2015-02-05	2025-12-19	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US20180044416A1 (en) *	2015-03-05	2018-02-15	Ucb Biopharma Sprl	Polymeric Fc proteins and methods of screening to alter their functional characteristics
WO2016149276A1 (en)	2015-03-16	2016-09-22	Genentech, Inc.	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN114907481A (zh)	2015-03-23	2022-08-16	震动疗法股份有限公司	Icos的抗体
PL3274370T3 (pl)	2015-03-23	2020-05-18	Bayer Pharma Aktiengesellschaft	Przeciwciała anty-ceacam6 i ich zastosowania
FR3034420A1 (fr)	2015-03-31	2016-10-07	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-cd303
CA2979732A1 (en)	2015-04-03	2016-10-06	Eureka Therapeutics, Inc.	Constructs targeting afp peptide/mhc complexes and uses thereof
CA2981183A1 (en)	2015-04-07	2016-10-13	Greg Lazar	Antigen binding complex having agonistic activity and methods of use
JP2018512856A (ja)	2015-04-17	2018-05-24	アルパインイミューンサイエンシズインコーポレイテッド	調整可能な親和性を有する免疫調節タンパク質
HRP20211159T1 (hr)	2015-04-24	2021-10-29	F. Hoffmann - La Roche Ag	Postupci identifikacije bakterija koje sadrže vezujuće polipeptide
JP2018520642A (ja)	2015-05-01	2018-08-02	ジェネンテック，インコーポレイテッド	マスク抗ｃｄ３抗体及びその使用方法
WO2016179194A1 (en)	2015-05-04	2016-11-10	Jounce Therapeutics, Inc.	Lilra3 and method of using the same
HK1248577A1 (zh)	2015-05-11	2018-10-19	F. Hoffmann-La Roche Ag	治疗狼疮性肾炎的组合物和方法
IL295002A (en)	2015-05-12	2022-09-01	Genentech Inc	Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
EP3763827A1 (en)	2015-05-29	2021-01-13	F. Hoffmann-La Roche AG	Pd-l1 promoter methylation in cancer
HK1248773A1 (zh)	2015-05-29	2018-10-19	豪夫迈‧罗氏有限公司	用於癌症的治疗和诊断方法
HK1250723A1 (zh)	2015-05-29	2019-01-11	F. Hoffmann-La Roche Ag	人源化抗埃博拉病毒糖蛋白抗体和使用方法
WO2016196228A1 (en)	2015-05-29	2016-12-08	Bristol-Myers Squibb Company	Antibodies against ox40 and uses thereof
EP3302552A1 (en)	2015-06-02	2018-04-11	H. Hoffnabb-La Roche Ag	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
CR20180013A (es)	2015-06-05	2018-12-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
EP3303397A1 (en)	2015-06-08	2018-04-11	H. Hoffnabb-La Roche Ag	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
MX2017014740A (es)	2015-06-08	2018-08-15	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
HK1255483A1 (zh)	2015-06-15	2019-08-16	基因泰克公司	抗体和免疫结合物
JP6871874B2 (ja)	2015-06-16	2021-05-19	ジェネンテック，インコーポレイテッド	ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
EP3310811B1 (en)	2015-06-16	2021-06-16	Genentech, Inc.	Anti-cd3 antibodies and methods of use
US10501545B2 (en)	2015-06-16	2019-12-10	Genentech, Inc.	Anti-CLL-1 antibodies and methods of use
HK1251493A1 (zh)	2015-06-17	2019-02-01	豪夫迈‧罗氏有限公司	使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
US10774145B2 (en)	2015-06-17	2020-09-15	Allakos Inc.	Methods and compositions for treating fibrotic diseases
EP3310812B1 (en)	2015-06-17	2025-07-30	F. Hoffmann-La Roche AG	Anti-her2 antibodies and methods of use
CN120665195A (zh)	2015-06-24	2025-09-19	豪夫迈·罗氏有限公司	具有定制亲和力的抗转铁蛋白受体抗体
EP3744732B1 (en)	2015-06-24	2025-09-10	F. Hoffmann-La Roche AG	Humanized anti-tau(ps422) antibodies and methods of use
JP7114460B2 (ja)	2015-06-26	2022-08-08	サノフィ・バイオテクノロジー	モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
ES2878316T3 (es)	2015-06-29	2021-11-18	Ventana Med Syst Inc	Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
CN108473573A (zh)	2015-06-29	2018-08-31	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于器官移植中
TWI741992B (zh)	2015-08-03	2021-10-11	美商百歐維拉提夫治療公司	因子ｉｘ融合蛋白以及其製備及使用方法
AU2016301380B2 (en)	2015-08-04	2021-07-01	Acceleron Pharma Inc.	Methods for treating myeloproliferative disorders
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3932953A1 (en)	2015-08-28	2022-01-05	F. Hoffmann-La Roche AG	Anti-hypusine antibodies and uses thereof
WO2017046746A1 (en)	2015-09-15	2017-03-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN108367004B (zh)	2015-09-21	2022-09-13	阿帕特夫研究和发展有限公司	Cd3结合多肽
EP3353206A1 (en)	2015-09-22	2018-08-01	Spring Bioscience Corporation	Anti-ox40 antibodies and diagnostic uses thereof
RU2763916C2 (ru)	2015-09-23	2022-01-11	Дженентек, Инк.	Оптимизированные варианты анти-vegf антител
JP6955487B2 (ja)	2015-09-24	2021-10-27	アブビトロ，エルエルシー	Ｈｉｖ抗体組成物および使用方法
HRP20241752T1 (hr)	2015-09-25	2025-02-28	F. Hoffmann - La Roche Ag	Anti-tigit protutijela i metode uporabe
AU2016332725A1 (en)	2015-09-29	2018-03-22	Celgene Corporation	PD-1 binding proteins and methods of use thereof
JP7628764B2 (ja)	2015-09-29	2025-02-12	アムジエン・インコーポレーテツド	Ａｓｇｒ阻害剤
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3150636A1 (en)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Tetravalent multispecific antibodies
AU2016333512B2 (en)	2015-10-02	2022-11-17	F. Hoffmann-La Roche Ag	Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
KR20180075537A (ko)	2015-10-06	2018-07-04	제넨테크, 인크.	다발성 경화증을 치료하기 위한 방법
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
EP3365372A1 (en)	2015-10-22	2018-08-29	Jounce Therapeutics, Inc.	Gene signatures for determining icos expression
WO2017074878A1 (en)	2015-10-25	2017-05-04	Sanofi	Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
EP3368568B1 (en)	2015-10-29	2022-04-06	F. Hoffmann-La Roche AG	Anti-variant fc-region antibodies and methods of use
EP3368074A2 (en)	2015-10-30	2018-09-05	Hoffmann-La Roche AG	Anti-factor d antibodies and conjugates
WO2017075212A1 (en)	2015-10-30	2017-05-04	Genentech, Inc.	Anti-htra1 antibodies and methods of use thereof
JP6998869B2 (ja)	2015-11-08	2022-02-04	ジェネンテック，インコーポレイテッド	多重特異性抗体のスクリーニング方法
KR102803158B1 (ko)	2015-12-02	2025-05-08	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
EP3383908A1 (en)	2015-12-02	2018-10-10	Stsciences, Inc.	Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
TWI868415B (zh)	2015-12-18	2025-01-01	日商中外製藥股份有限公司	抗肌抑素抗體、含變異fc區之多肽及使用方法
CR20180364A (es)	2015-12-18	2018-08-22	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-c5 y métodos de uso
WO2017102920A1 (en)	2015-12-18	2017-06-22	Intervet International B.V.	Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
JP7304697B2 (ja)	2015-12-23	2023-07-07	ムーンショットファーマエルエルシー	未成熟終止コドンのリードスルーを促進することにより免疫反応を誘発するための方法
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
EP3400246B1 (en)	2016-01-08	2020-10-21	H. Hoffnabb-La Roche Ag	Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
CA3011739A1 (en)	2016-01-20	2017-07-27	Genentech, Inc.	High dose treatments for alzheimer's disease
LT3411478T (lt)	2016-02-01	2022-09-26	Bioverativ Therapeutics Inc.	Optimizuoti viii faktoriaus genai
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
CA3016187A1 (en)	2016-03-04	2017-09-08	Bristol-Myers Squibb Company	Combination therapy with anti-cd73 antibodies
AU2017231749A1 (en)	2016-03-08	2018-09-20	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
EP4112641A1 (en)	2016-03-15	2023-01-04	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN108700598A (zh)	2016-03-25	2018-10-23	豪夫迈·罗氏有限公司	多路总抗体和抗体缀合的药物量化测定法
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
RS64771B1 (sr)	2016-04-13	2023-11-30	Sanofi Sa	Trispecifični i/ili trovalentni vezujući proteini
CN109476732B (zh)	2016-04-13	2024-03-22	赛诺菲	三特异性和/或三价结合蛋白
US20170319688A1 (en)	2016-04-14	2017-11-09	Genentech, Inc.	Anti-rspo3 antibodies and methods of use
CN109154613A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
WO2017181079A2 (en)	2016-04-15	2017-10-19	Genentech, Inc.	Methods for monitoring and treating cancer
KR102824067B1 (ko)	2016-04-15	2025-06-23	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP7527758B2 (ja)	2016-04-15	2024-08-05	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｄ８０バリアント免疫調節タンパク質およびその使用
CN109328069B (zh)	2016-04-15	2023-09-01	亿一生物医药开发(上海)有限公司	Il-22在治疗坏死性小肠结肠炎中的用途
CN109563164A (zh)	2016-04-15	2019-04-02	生物蛋白有限公司	抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
MX2018013342A (es)	2016-05-02	2019-05-09	Hoffmann La Roche	Polipeptido de fusion multicircular "contorsbody" - ligante de diana de cadena sencilla.
MX392069B (es)	2016-05-09	2025-03-21	Bristol Myers Squibb Co	Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
MX394735B (es)	2016-05-13	2025-03-24	Bioatla Llc	Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
ES2858151T3 (es)	2016-05-20	2021-09-29	Hoffmann La Roche	Conjugados de PROTAC-anticuerpo y procedimientos de uso
JP7022080B2 (ja)	2016-05-27	2022-02-17	ジェネンテック，インコーポレイテッド	部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
CN109476648B (zh)	2016-06-06	2022-09-13	豪夫迈·罗氏有限公司	司维司群抗体-药物缀合物和使用方法
EP3472200B1 (en)	2016-06-17	2026-01-28	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
CN109563160B (zh)	2016-06-24	2023-02-28	豪夫迈·罗氏有限公司	抗聚泛素多特异性抗体
EP4410378A3 (en)	2016-07-01	2024-10-09	Resolve Therapeutics, LLC	Optimized binuclease fusions and methods
EP3478717B1 (en)	2016-07-04	2022-01-05	F. Hoffmann-La Roche AG	Novel antibody format
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
US20200148750A1 (en)	2016-07-21	2020-05-14	Emory University	Ebola Virus Antibodies and Binding Agents Derived Therefrom
WO2018022946A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
BR112019001179A2 (pt)	2016-07-29	2019-04-30	Chugai Seiyaku Kabushiki Kaisha	anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
KR102102734B1 (ko)	2016-08-05	2020-04-22	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
CN109963871A (zh)	2016-08-05	2019-07-02	豪夫迈·罗氏有限公司	具有激动活性的多价及多表位抗体以及使用方法
WO2018029124A1 (en)	2016-08-08	2018-02-15	F. Hoffmann-La Roche Ag	Therapeutic and diagnostic methods for cancer
WO2018031662A1 (en)	2016-08-11	2018-02-15	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN109963868B (zh)	2016-08-22	2023-11-14	醣基生医股份有限公司	抗体、结合片段及使用方法
MY199683A (en)	2016-09-16	2023-11-16	Shanghai Henlius Biotech Inc	Anti-pd-1 antibodies
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en)	2016-09-19	2023-11-22	F. Hoffmann-La Roche AG	Complement factor based affinity chromatography
SG11201901950TA (en)	2016-09-19	2019-04-29	Celgene Corp	Methods of treating immune disorders using pd-1 binding proteins
JP2019534859A (ja)	2016-09-19	2019-12-05	セルジーンコーポレイション	Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
EP4360714A3 (en)	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
CN110035769A (zh)	2016-09-21	2019-07-19	奈斯科尔公司	针对siglec-15的抗体及其使用方法
RS64550B1 (sr)	2016-09-23	2023-09-29	Hoffmann La Roche	Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
CN110139674B (zh)	2016-10-05	2023-05-16	豪夫迈·罗氏有限公司	制备抗体药物缀合物的方法
CA3038712A1 (en)	2016-10-06	2018-04-12	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
EP3532091A2 (en)	2016-10-29	2019-09-04	H. Hoffnabb-La Roche Ag	Anti-mic antibidies and methods of use
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019004834A (es)	2016-11-02	2019-06-20	Jounce Therapeutics Inc	Anticuerpos de pd-1 y usos de estos.
CN109923128A (zh)	2016-11-15	2019-06-21	基因泰克公司	用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
JOP20190100A1 (ar)	2016-11-19	2019-05-01	Potenza Therapeutics Inc	بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JP7313684B2 (ja)	2016-11-21	2023-07-25	キュレアブゲーエムベーハー	抗ｇｐ７３抗体及びイムノコンジュゲート
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN110520149A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	诱导对凝血因子的免疫耐受性的方法
IL266911B2 (en)	2016-12-07	2024-10-01	Genentech Inc	Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
TWI789371B (zh)	2016-12-07	2023-01-11	美商建南德克公司	抗-ｔａｕ抗體及使用方法
JP2020511408A (ja)	2016-12-12	2020-04-16	ジェネンテック，インコーポレイテッド	抗ｐｄ−ｌ１抗体及び抗アンドロゲン薬を使用してがんを治療する方法
EP3559034B1 (en)	2016-12-20	2020-12-02	H. Hoffnabb-La Roche Ag	Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JOP20190134A1 (ar)	2016-12-23	2019-06-02	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
US20180230218A1 (en)	2017-01-04	2018-08-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
WO2018129332A1 (en)	2017-01-06	2018-07-12	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
EP3565586B1 (en)	2017-01-06	2025-10-08	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
SG10202107429WA (en)	2017-01-06	2021-08-30	Avidity Biosciences Inc	Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US11274157B2 (en)	2017-01-12	2022-03-15	Eureka Therapeutics, Inc.	Constructs targeting histone H3 peptide/MHC complexes and uses thereof
US20190367599A1 (en)	2017-01-31	2019-12-05	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3580240A1 (en)	2017-02-10	2019-12-18	H. Hoffnabb-La Roche Ag	Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201907606XA (en)	2017-02-27	2019-09-27	Regeneron Pharma	Humanized model of kidney and liver disorders
EP3589754B1 (en)	2017-03-01	2023-06-28	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for cancer
CA3053804C (en)	2017-03-16	2025-09-23	Alpine Immune Sciences, Inc.	Immunomodulatory Proteins of PD-L1 Variants and Associated Uses
MX2019010887A (es)	2017-03-16	2019-10-15	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras de cb80 variante y usos de estas.
US11732022B2 (en)	2017-03-16	2023-08-22	Alpine Immune Sciences, Inc.	PD-L2 variant immunomodulatory proteins and uses thereof
MX2019011141A (es)	2017-03-22	2019-11-05	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
CN110494446A (zh)	2017-03-28	2019-11-22	基因泰克公司	治疗神经退行性疾病的方法
JOP20190203A1 (ar)	2017-03-30	2019-09-03	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US20200024351A1 (en)	2017-04-03	2020-01-23	Jounce Therapeutics, Inc.	Compositions and Methods for the Treatment of Cancer
PE20210256A1 (es)	2017-04-05	2021-02-10	Hoffmann La Roche	Anticuerpos anti-lag3
EP3606952A1 (en)	2017-04-07	2020-02-12	Miltenyi Biotec GmbH	POLYPEPTIDES WITH MUTANT HUMAN IgG4
CA3058282A1 (en)	2017-04-14	2018-10-18	Gamamabs Pharma	Amhrii-binding compounds for preventing or treating cancers
WO2018191660A1 (en)	2017-04-14	2018-10-18	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
KR20250017758A (ko)	2017-04-14	2025-02-04	엑셀리시스, 인코포레이티드	폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물
TW201841656A (zh)	2017-04-21	2018-12-01	美商建南德克公司	Ｋｌｋ５拮抗劑用於治療疾病之用途
CA3059820A1 (en)	2017-04-26	2018-11-01	Eureka Therapeutics, Inc.	Constructs specifically recognizing glypican 3 and uses thereof
EP3615572A1 (en)	2017-04-27	2020-03-04	Tesaro Inc.	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EP4241848A3 (en)	2017-05-04	2023-11-01	Acceleron Pharma Inc.	Tgf-beta receptor type ii fusion proteins and uses thereof
EP3618868A4 (en)	2017-05-05	2021-02-24	Allakos Inc.	METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
TW201904578A (zh)	2017-05-10	2019-02-01	美商艾歐凡斯生物治療公司	源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
US11116835B2 (en)	2017-05-10	2021-09-14	Fred Hutchinson Cancer Research Center	Epstein Barr virus antibodies, vaccines, and uses of the same
WO2018218056A1 (en)	2017-05-25	2018-11-29	Birstol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
JP7768666B2 (ja)	2017-05-31	2025-11-12	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7369038B2 (ja)	2017-05-31	2023-10-25	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
CN121248782A (zh)	2017-06-06	2026-01-02	斯特库伯株式会社	使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
EP3642239A1 (en)	2017-06-20	2020-04-29	Amgen Inc.	Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EP3641752A4 (en)	2017-06-22	2021-03-17	Moonshot Pharma LLC	METHOD OF TREATMENT OF CANCER WITH COMPOSITIONS WITH AMLEXANOX AND IMMUNE MODULATORS
EA202090020A1 (ru)	2017-07-10	2020-04-28	Интернэшнл - Драг - Дивелопмент - Байотек	Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
BR112020000719A2 (pt)	2017-07-11	2020-07-14	Compass Therapeutics Llc	anticorpos agonistas que ligam o cd137 humano e seus usos
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
TWI823859B (zh)	2017-07-21	2023-12-01	美商建南德克公司	癌症之治療及診斷方法
SG11202000658PA (en)	2017-07-26	2020-02-27	Forty Seven Inc	Anti-sirp-alpha antibodies and related methods
IL322212A (en)	2017-08-09	2025-09-01	Bioverativ Therapeutics Inc	Nucleic acid molecules and their uses
EP3684811A2 (en)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
MX2020002070A (es)	2017-08-22	2020-03-24	Sanabio Llc	Receptores solubles de interferon y usos de los mismos.
JP7241080B2 (ja)	2017-08-28	2023-03-16	アンジーエックス・インコーポレーテッド	抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
EP3684413A1 (en)	2017-09-20	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2019071028A1 (en)	2017-10-04	2019-04-11	Avidity Biosciences Llc	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
EP3694882B1 (en)	2017-10-10	2024-06-19	Sanofi	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
KR20250020681A (ko)	2017-10-10	2025-02-11	알파인 이뮨 사이언시즈, 인코포레이티드	Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3185107A1 (en)	2017-10-12	2019-04-18	Immunowake Inc.	Vegfr-antibody light chain fusion protein
TWI899046B (zh)	2017-10-18	2025-10-01	美商艾爾潘免疫科學有限公司	變異型icos 配位體免疫調節蛋白及相關組合物及方法
MX2020003497A (es)	2017-10-20	2020-07-22	Hoffmann La Roche	Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
AU2018358883B2 (en)	2017-10-30	2025-09-25	F. Hoffmann-La Roche Ag	Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
PL3707510T3 (pl)	2017-11-06	2024-09-30	F. Hoffmann-La Roche Ag	Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
JP7731196B2 (ja)	2017-11-14	2025-08-29	中外製薬株式会社	抗Ｃ１ｓ抗体および使用方法
EP3713961A2 (en)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3714041A1 (en)	2017-11-22	2020-09-30	Iovance Biotherapeutics, Inc.	Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
BR112020010753A2 (pt)	2017-12-01	2020-11-24	The Regents Of The University Of California	anticorpos anti-cxcr5 e composições e usos dos mesmos
WO2019113393A1 (en)	2017-12-06	2019-06-13	Avidity Biosciences Llc	Compositions and methods of treating muscle atrophy and myotonic dystrophy
EP3724885A2 (en)	2017-12-15	2020-10-21	Iovance Biotherapeutics, Inc.	Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3498293A1 (en)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019126536A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals Inc.	Humanized anti-cd200 antibodies and uses thereof
WO2019126133A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
EP3728321A1 (en)	2017-12-22	2020-10-28	F. Hoffmann-La Roche AG	Use of pilra binding agents for treatment of a disease
EP3728318A2 (en)	2017-12-22	2020-10-28	Jounce Therapeutics, Inc.	Antibodies for lilrb2
CN111542543B (zh)	2017-12-28	2023-12-22	南京传奇生物科技有限公司	针对pd-l1的抗体及其变体
SG11202004158QA (en)	2017-12-28	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against tigit
EP3731865A1 (en)	2017-12-29	2020-11-04	F. Hoffmann-La Roche AG	Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
FR3076294B1 (fr)	2017-12-29	2022-01-28	Lab Francais Du Fractionnement	Procede de purification d'anticorps a partir de lait brut
SG11202006148UA (en)	2018-01-03	2020-07-29	Alpine Immune Sciences Inc	Multi-domain immunomodulatory proteins and methods of use thereof
US20220153871A1 (en)	2018-01-04	2022-05-19	Iconic Therapeutics, Inc.	Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
AU2019205090A1 (en)	2018-01-05	2020-08-06	Ac Immune Sa	Misfolded TDP-43 binding molecules
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3084518A1 (en)	2018-01-15	2019-07-18	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against pd-1
CA3088649A1 (en)	2018-01-16	2019-07-25	Lakepharma, Inc.	Bispecific antibody that binds cd3 and another target
EP3743437A1 (en)	2018-01-26	2020-12-02	F. Hoffmann-La Roche AG	Il-22 fc fusion proteins and methods of use
SI3743088T1 (sl)	2018-01-26	2023-01-31	F. Hoffmann - La Roche Ag	Farmacevtski sestavki IL-22 Fc in načini njihove uporabe
MX2020008152A (es)	2018-02-01	2020-11-24	Bioverativ Therapeutics Inc	Uso de vectores lentivirales que expresan el factor viii.
CA3081125C (en)	2018-02-01	2025-09-16	Innovent Biologics (Suzhou) Co., Ltd.	All-Human Single-Chain Variable Fragment Anti-Antigen for B Lymphocyte Maturation (BCMA), and Associated Application
EP3749361A1 (en)	2018-02-08	2020-12-16	F. Hoffmann-La Roche AG	Bispecific antigen-binding molecules and methods of use
CA3090538A1 (en)	2018-02-09	2019-08-15	Acceleron Pharma, Inc.	Methods for treating heterotopic ossification
BR112020016172A2 (pt)	2018-02-09	2020-12-15	Genentech, Inc.	Métodos de tratamento, métodos para determinar, métodos para selecionar uma terapia, métodos para avaliar uma resposta e monitorar a resposta, kits para identificar um paciente, agentes selecionados, agentes para uso, uso de um agente selecionado e uso de um antagonista
MA51875A (fr)	2018-02-13	2020-12-23	Iovance Biotherapeutics Inc	Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CN111757894B (zh)	2018-02-14	2025-02-25	Abba疗法股份公司	抗人类pd-l2抗体
CN111757751A (zh)	2018-02-21	2020-10-09	豪夫迈·罗氏有限公司	用于使用IL-22 Fc融合蛋白的治疗的剂量方案
CA3092108A1 (en)	2018-02-26	2019-08-29	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20210002373A1 (en)	2018-03-01	2021-01-07	Nextcure, Inc.	KLRG1 Binding Compositions and Methods of Use Thereof
CA3092002A1 (en)	2018-03-13	2019-09-19	F. Hoffmann-La Roche Ag	Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178269A2 (en)	2018-03-14	2019-09-19	Surface Oncology, Inc.	Antibodies that bind cd39 and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
US11891432B2 (en)	2018-03-15	2024-02-06	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
US12202894B2 (en)	2018-03-20	2025-01-21	WuXi Biologics Ireland Limited	Anti-TIM-3 antibodies
US11661452B2 (en)	2018-03-20	2023-05-30	WuXi Biologics Ireland Limited	Anti-lag-3 antibody polypeptide
EP3768317A4 (en)	2018-03-22	2021-12-22	Surface Oncology, Inc.	ANTI-IL-27 ANTIBODIES AND USES THEREOF
PE20210313A1 (es)	2018-03-28	2021-02-12	Bristol Myers Squibb Co	Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
JP2021519758A (ja)	2018-03-29	2021-08-12	ファイザーインコーポレイティッド	Ｌｆａ３バリアントならびにその組成物および使用法
SG11202009542PA (en)	2018-03-29	2020-10-29	Genentech Inc	Modulating lactogenic activity in mammalian cells
KR102876940B1 (ko)	2018-03-30	2025-10-24	난징 레전드 바이오테크 씨오., 엘티디.	Lag-3에 대한 단일-도메인 항체 및 이의 용도
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
CR20250325A (es)	2018-04-13	2025-08-29	Genentech Inc	Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
CN110464842B (zh)	2018-05-11	2022-10-14	信达生物制药(苏州)有限公司	包含抗pcsk9抗体的制剂及其用途
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
BR112020023118A2 (pt)	2018-05-14	2021-04-13	Werewolf Therapeutics, Inc.	Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
MA52630B1 (fr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Procédés de traitement de l'hémophilie a
US11987629B2 (en)	2018-06-01	2024-05-21	Tayu Huaxia Biotech Medical Group Co., Ltd.	Compositions and uses thereof for treating disease or condition
WO2019227490A1 (en)	2018-06-01	2019-12-05	Tayu Huaxia Biotech Medical Group Co., Ltd.	Compositions and methods for imaging
US12037398B2 (en)	2018-06-04	2024-07-16	Biogen Ma Inc.	Anti-VLA-4 antibodies having reduced effector function
JP7372237B2 (ja)	2018-06-04	2023-10-31	中外製薬株式会社	細胞質内での半減期が変化した抗原結合分子
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
JP2021526837A (ja)	2018-06-12	2021-10-11	アンジーエックス・インコーポレーテッド	抗体−オリゴヌクレオチドコンジュゲート
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
CA3103936A1 (en)	2018-06-18	2019-12-26	Eureka Therapeutics, Inc.	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
MY205645A (en)	2018-06-23	2024-11-02	Genentech Inc	Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
AU2019297451A1 (en)	2018-07-03	2021-01-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
CN112601517A (zh)	2018-07-03	2021-04-02	百时美施贵宝公司	Fgf-21配制品
WO2020014306A1 (en)	2018-07-10	2020-01-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
AU2019305637A1 (en)	2018-07-18	2021-03-11	Genentech, Inc.	Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
SG11202100373VA (en)	2018-07-20	2021-02-25	Surface Oncology Inc	Anti-cd112r compositions and methods
KR20210040827A (ko)	2018-07-25	2021-04-14	이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드	항 tigit 항체 및 그 용도
SMT202400271T1 (it)	2018-08-01	2024-07-09	Chugai Pharmaceutical Co Ltd	Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5
CN113286824A (zh)	2018-08-03	2021-08-20	中外制药株式会社	包含两个彼此连接的抗原结合结构域的抗原结合分子
CN113227385B (zh)	2018-08-09	2024-12-24	比奥维拉迪维治疗股份有限公司	核酸分子及其用于非病毒基因疗法的用途
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
US12460004B2 (en)	2018-08-09	2025-11-04	Compass Therapeutics Llc	Antibodies that bind CD277 and uses thereof
EP3608674A1 (en)	2018-08-09	2020-02-12	Regeneron Pharmaceuticals, Inc.	Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
EP3833443A1 (en)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antigen binding agents that bind cd277 and uses thereof
WO2020033827A1 (en)	2018-08-10	2020-02-13	Genentech, Inc.	Cell culture strategies for modulating protein glycosylation
CN112839960B (zh)	2018-08-10	2024-09-06	中外制药株式会社	抗cd137抗原结合分子及其应用
US12259395B2 (en)	2018-08-17	2025-03-25	Ab Studio Inc.	Catabodies and methods of use thereof
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
TW202031273A (zh)	2018-08-31	2020-09-01	美商艾歐凡斯生物治療公司	抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
PE20211605A1 (es)	2018-09-07	2021-08-23	Pfizer	ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
WO2020052542A1 (en)	2018-09-10	2020-03-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cll1 and constructs thereof
EP3849565A4 (en)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
EP3853247A2 (en)	2018-09-19	2021-07-28	Alpine Immune Sciences, Inc.	Methods and uses of variant cd80 fusion proteins and related constructs
AU2019342099A1 (en)	2018-09-19	2021-04-08	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
JP7475336B2 (ja)	2018-09-21	2024-04-26	ジェネンテック，インコーポレイテッド	トリプルネガティブ乳癌のための診断方法
KR20210069058A (ko)	2018-09-26	2021-06-10	지앙수 헨그루이 메디슨 컴퍼니 리미티드	항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
EP3856764A4 (en)	2018-09-27	2022-11-02	Xilio Development, Inc.	MASKED CYTOKINE POLYPEPTIDES
PE20211491A1 (es)	2018-09-27	2021-08-11	Celgene Corp	PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
CN113166254A (zh)	2018-10-09	2021-07-23	赛诺菲	三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
WO2020081493A1 (en)	2018-10-16	2020-04-23	Molecular Templates, Inc.	Pd-l1 binding proteins
KR20210079311A (ko)	2018-10-18	2021-06-29	제넨테크, 인크.	육종성 신장암에 대한 진단과 치료 방법
MA54052A (fr)	2018-10-29	2022-02-09	Hoffmann La Roche	Formulation d'anticorps
EP3873944A1 (en)	2018-10-31	2021-09-08	Bayer Aktiengesellschaft	Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
SG11202104104VA (en)	2018-11-05	2021-05-28	Genentech Inc	Methods of producing two chain proteins in prokaryotic host cells
SG11202104663PA (en)	2018-11-05	2021-06-29	Iovance Biotherapeutics Inc	Treatment of nsclc patients refractory for anti-pd-1 antibody
MX2021005751A (es)	2018-11-16	2021-10-01	Memorial Sloan Kettering Cancer Center	Anticuerpos contra mucina 16 y métodos de uso de los mismos.
CA3101670C (en)	2018-11-27	2024-02-06	Innovent Biologics (Suzhou) Co., Ltd.	Anti-il-23p19 antibody and use thereof
CA3120729A1 (en)	2018-11-27	2020-06-04	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
CN113348177A (zh)	2018-11-28	2021-09-03	百时美施贵宝公司	包含经修饰的重链恒定区的抗体
KR20210135987A (ko)	2018-11-30	2021-11-16	알파인 이뮨 사이언시즈, 인코포레이티드	Cd86 변이체 면역조절 단백질 및 그의 용도
JP2022513708A (ja)	2018-12-05	2022-02-09	モルフォシス・アーゲー	多重特異性抗原結合分子
JP7671248B2 (ja)	2018-12-05	2025-05-01	ジェネンテック，インコーポレイテッド	がんの免疫療法のための診断方法及び診断用組成物
KR20210100668A (ko)	2018-12-06	2021-08-17	제넨테크, 인크.	항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
WO2020118011A1 (en)	2018-12-06	2020-06-11	Alexion Pharmaceuticals, Inc.	Anti-alk2 antibodies and uses thereof
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
SG11202105161YA (en)	2018-12-13	2021-06-29	Surface Oncology Inc	Anti-il-27 antibodies and uses thereof
EP3898688A1 (en)	2018-12-18	2021-10-27	Catapult Therapeutics B.V.	The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
TW202035442A (zh)	2018-12-20	2020-10-01	美商建南德克公司	經修飾之抗體Fc及其使用方法
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
CN113195531B (zh)	2018-12-21	2025-03-04	豪夫迈·罗氏有限公司	与VEGF和IL-1β结合的抗体及其使用方法
JP2022514950A (ja)	2018-12-21	2022-02-16	２３アンドミー・インコーポレイテッド	抗ｉｌ－３６抗体およびその使用方法
CN111349162A (zh)	2018-12-21	2020-06-30	神州细胞工程有限公司	人源化抗pd-1抗体及其用途
KR102910209B1 (ko)	2018-12-21	2026-01-09	제넨테크, 인크.	세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
CN113490687A (zh)	2018-12-26	2021-10-08	西利欧发展公司	抗ctla4抗体和其使用方法
WO2020141145A1 (en)	2018-12-30	2020-07-09	F. Hoffmann-La Roche Ag	Anti-rabbit cd19 antibodies and methods of use
EP3906062A1 (en)	2019-01-04	2021-11-10	Resolve Therapeutics, LLC	Treatment of sjogren's disease with nuclease fusion proteins
MX2021008434A (es)	2019-01-14	2021-09-23	Genentech Inc	Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
BR112021013571A2 (pt)	2019-01-16	2021-09-21	Compass Therapeutics Llc	Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
CN113329763A (zh)	2019-01-22	2021-08-31	豪夫迈·罗氏有限公司	免疫球蛋白a抗体以及制备和使用方法
KR20210119448A (ko)	2019-01-23	2021-10-05	앙세파	Cd31 경쟁인자(competitor) 및 이의 용도
US12263234B2 (en)	2019-01-23	2025-04-01	Tayu Huaxia Biotech Medical Group Co., Ltd.	Anti-PD-L1 diabodies and the use thereof
CA3124515A1 (en)	2019-01-23	2020-07-30	Genentech, Inc.	Methods of producing multimeric proteins in eukaryotic host cells
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
AU2020224681A1 (en)	2019-02-21	2021-09-16	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
SG11202109061YA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US12331119B2 (en) *	2019-02-22	2025-06-17	Wuhan Yzy Biopharma Co., Ltd.	Modified Fc fragment, antibody comprising same, and application thereof
KR20210133237A (ko)	2019-02-27	2021-11-05	제넨테크, 인크.	항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
CN113874051A (zh)	2019-02-27	2021-12-31	安吉克公司	包含抗tm4sf1抗体的抗体-药物缀合物及其使用方法
WO2020180733A1 (en)	2019-03-01	2020-09-10	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
KR102866290B1 (ko)	2019-03-08	2025-10-01	제넨테크, 인크.	세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
EP3938396A1 (en)	2019-03-11	2022-01-19	Jounce Therapeutics, Inc.	Anti-icos antibodies for the treatment of cancer
JP7730761B2 (ja)	2019-03-14	2025-08-28	ジェネンテック，インコーポレイテッド	抗ＨＥＲ２ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置
WO2020206063A1 (en)	2019-04-03	2020-10-08	Genzyme Corporation	Anti-alpha beta tcr binding polypeptides with reduced fragmentation
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
KR20220035032A (ko)	2019-04-17	2022-03-21	알파인 이뮨 사이언시즈, 인코포레이티드	변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도
TW202043291A (zh)	2019-04-19	2020-12-01	美商建南德克公司	抗mertk抗體及使用方法
AU2020257748A1 (en)	2019-04-19	2021-11-18	Chugai Seiyaku Kabushiki Kaisha	Chimeric receptor recognizing modification site of antibody
US12497615B2 (en)	2019-04-25	2025-12-16	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
TWI879768B (zh)	2019-05-03	2025-04-11	美商建南德克公司	用抗pd-l1抗體治療癌症之方法
WO2020232305A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
AU2020275415B2 (en)	2019-05-14	2026-01-15	Genentech, Inc.	Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
KR20220012270A (ko)	2019-05-23	2022-02-03	에이씨 이뮨 에스.에이.	항-tdp-43 결합 분자 및 이의 용도
CN114375297A (zh)	2019-06-06	2022-04-19	艾维迪提生物科学公司	Una亚酰胺及其用途
CA3142283A1 (en)	2019-06-06	2020-12-10	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
US20220348658A1 (en)	2019-06-10	2022-11-03	Chugai Seiyaku Kabushiki Kaisha	Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
US20220387608A1 (en)	2019-06-18	2022-12-08	Bayer Aktiengesellschaft	Adrenomedullin-analogues for long-term stabilization and their use
CN114245807B (zh)	2019-06-25	2025-05-02	吉利德科学公司	Flt3l-fc融合蛋白和使用方法
CA3145139A1 (en)	2019-07-09	2021-01-14	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing pseudomonas pcrv and uses thereof
MX2022000111A (es)	2019-07-10	2022-02-10	Chugai Pharmaceutical Co Ltd	Moleculas de union a claudina-6 y usos de las mismas.
WO2021005232A1 (en)	2019-07-11	2021-01-14	Umc Utrecht Holding B.V.	Intranasal administration of neutralising antiviral antibodies
JPWO2021010326A1 (da)	2019-07-12	2021-01-21
AR119382A1 (es)	2019-07-12	2021-12-15	Hoffmann La Roche	Anticuerpos de pre-direccionamiento y métodos de uso
AU2020316498B2 (en)	2019-07-19	2024-02-29	Sinocelltech Ltd.	Humanized anti-VEGF monoclonal antibody
AU2020316495B2 (en)	2019-07-19	2024-07-04	Sinocelltech Ltd	Humanized anti-VEGF Fab antibody fragment and use thereof
CN114787373A (zh)	2019-07-25	2022-07-22	免疫苏醒公司	测量通过效应子进行的细胞介导的杀伤的方法
CN114286827B (zh)	2019-07-26	2024-01-12	神州细胞工程有限公司	人源化抗il17a抗体及其应用
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
WO2021019036A1 (en)	2019-07-31	2021-02-04	F. Hoffmann-La Roche Ag	Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
CN114466660A (zh)	2019-07-31	2022-05-10	豪夫迈·罗氏有限公司	通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
CN114641490B (zh)	2019-08-06	2023-06-06	新旭生技股份有限公司	结合至病理性tau种类的抗体及其用途
EP4438057A3 (en)	2019-09-12	2025-01-01	F. Hoffmann-La Roche AG	Compositions and methods of treating lupus nephritis
CN114450024A (zh)	2019-09-16	2022-05-06	表面肿瘤学公司	抗cd39抗体组合物和方法
US11918649B2 (en)	2019-09-18	2024-03-05	Molecular Templates, Inc.	PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
EP4031579A2 (en)	2019-09-18	2022-07-27	F. Hoffmann-La Roche AG	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2022003266A (es)	2019-09-20	2022-04-11	Genentech Inc	Dosis para anticuerpos anti-triptasa.
MX2022003719A (es)	2019-09-25	2022-04-26	Surface Oncology Inc	Anticuerpos anti-il-27 y sus usos.
KR20220088428A (ko)	2019-09-26	2022-06-27	주식회사 에스티큐브앤컴퍼니	글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
AU2020351734A1 (en)	2019-09-27	2022-04-14	Genentech, Inc.	Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
EP4034160A1 (en)	2019-09-27	2022-08-03	Janssen Biotech, Inc.	Anti-ceacam antibodies and uses thereof
TW202126284A (zh)	2019-09-30	2021-07-16	美商百歐維拉提夫治療公司	慢病毒載體配製物
CA3154710A1 (en)	2019-10-04	2021-04-08	TAE Life Sciences	Antibody compositions comprising fc mutations and site-specific conjugation properties
CN114829404B (zh)	2019-10-09	2025-09-09	斯特库比公司	对糖基化的lag3特异的抗体及其使用方法
CA3153880A1 (en)	2019-10-18	2020-06-09	Juana Elva HERNANDEZ MONTALVO	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
CN114787188A (zh)	2019-11-05	2022-07-22	震动疗法股份有限公司	用抗pd-1抗体治疗癌症的方法
JP2022553803A (ja)	2019-11-06	2022-12-26	ジェネンテック，インコーポレイテッド	血液がんの処置のための診断方法及び治療方法
WO2021096888A1 (en)	2019-11-12	2021-05-20	Foundation Medicine, Inc.	Methods of detecting a fusion gene encoding a neoantigen
EP4058471A1 (en)	2019-11-14	2022-09-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
EP3825330A1 (en)	2019-11-19	2021-05-26	International-Drug-Development-Biotech	Anti-cd117 antibodies and methods of use thereof
KR20220113790A (ko)	2019-12-13	2022-08-16	제넨테크, 인크.	항-ly6g6d 항체 및 사용 방법
JP7751581B2 (ja)	2019-12-20	2025-10-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｉｌ－３７融合タンパク質及びその使用
CN113045655A (zh)	2019-12-27	2021-06-29	高诚生物医药(香港)有限公司	抗ox40抗体及其用途
KR20240035914A (ko)	2019-12-27	2024-03-18	추가이 세이야쿠 가부시키가이샤	항ctla-4 항체 및 그의 사용
EP4084823A4 (en)	2020-01-03	2024-05-15	Marengo Therapeutics, Inc.	ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
US11859000B2 (en)	2020-01-06	2024-01-02	Vaccinex Inc.	Anti-CCR8 antibodies and uses thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2021148983A1 (en)	2020-01-24	2021-07-29	Pfizer Inc.	Anti-e-selectin antibodies, compositions and methods of use
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN116650628A (zh)	2020-01-31	2023-08-29	基因泰克公司	用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
EP4097143A1 (en)	2020-01-31	2022-12-07	The Cleveland Clinic Foundation	Anti-müllerian hormone receptor 2 antibodies and methods of use
KR20220139915A (ko)	2020-02-06	2022-10-17	브리스톨-마이어스 스큅 컴퍼니	Il-10 및 그의 용도
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
AU2021219668B2 (en)	2020-02-14	2025-06-12	Gilead Sciences, Inc.	Antibodies and fusion proteins that bind to CCR8 and uses thereof
EP4106794A4 (en)	2020-02-19	2024-03-20	Evive Biotechnology (Shanghai) Ltd	METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
KR20220148235A (ko)	2020-02-28	2022-11-04	젠자임 코포레이션	최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
WO2021170071A1 (en)	2020-02-28	2021-09-02	Shanghai Henlius Biotech, Inc.	Anti-cd137 constructs, multispecific antibody and uses thereof
BR112022016491A2 (pt)	2020-02-28	2022-10-11	Shanghai Henlius Biotech Inc	Construto anti-cd137 e usos do mesmo
US11896619B2 (en)	2020-03-10	2024-02-13	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230340114A1 (en)	2020-03-12	2023-10-26	Immune-Onc Therapeutics, Inc.	Novel anti-lilrb4 antibodies and derivative products
JP7767298B2 (ja)	2020-03-13	2025-11-11	ジェネンテック，インコーポレイテッド	抗インターロイキン－３３抗体及びその使用
KR102811560B1 (ko)	2020-03-19	2025-05-22	제넨테크, 인크.	동종형 선택적 항-tgf-베타 항체 및 이용 방법
CA3172111A1 (en)	2020-03-19	2021-09-23	Barbora MALECOVA	Compositions and methods of treating facioscapulohumeral muscular dystrophy
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
EP4107184A1 (en)	2020-03-23	2022-12-28	Genentech, Inc.	Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
WO2021194860A1 (en)	2020-03-23	2021-09-30	Genentech, Inc.	Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
WO2021194861A1 (en)	2020-03-23	2021-09-30	Genentech, Inc.	Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
MX2022011752A (es)	2020-03-24	2022-10-18	Genentech Inc	Agentes de fijacion a tie2 y metodos de uso.
EP4127153A2 (en)	2020-03-26	2023-02-08	Genentech, Inc.	Modified mammalian cells having reduced host cell proteins
EP4126940A1 (en)	2020-03-30	2023-02-08	F. Hoffmann-La Roche AG	Antibody that binds to vegf and pdgf-b and methods of use
KR20220161337A (ko)	2020-04-01	2022-12-06	쿄와 기린 가부시키가이샤	항체 조성물
CN115698717A (zh)	2020-04-03	2023-02-03	基因泰克公司	癌症的治疗和诊断方法
TW202204622A (zh)	2020-04-09	2022-02-01	大陸商蘇州艾博生物科技有限公司	針對冠狀病毒之核酸疫苗
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2021216417A1 (en)	2020-04-20	2021-10-28	Jounce Therapeutics, Inc.	Compositions and methods for vaccination and the treatment of infectious diseases
BR112022021441A2 (pt)	2020-04-24	2022-12-13	Genentech Inc	Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
JP2023522417A (ja)	2020-04-24	2023-05-30	エフ．ホフマン－ラロシュアーゲー	スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
CA3178882A1 (en)	2020-05-08	2021-11-11	Alpine Immune Sciences, Inc.	April and baff inhibitory immunomodulatory proteins and methods of use thereof
US20230192867A1 (en)	2020-05-15	2023-06-22	Bristol-Myers Squibb Company	Antibodies to garp
US20230220057A1 (en)	2020-05-27	2023-07-13	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing nerve growth factor and uses thereof
EP3915641A1 (en)	2020-05-27	2021-12-01	International-Drug-Development-Biotech	Anti-cd5 antibodies and methods of use thereof
JP2023528375A (ja)	2020-05-29	2023-07-04	２３アンドミー・インコーポレイテッド	抗ｃｄ２００ｒ１抗体及びその使用方法
CN116529260A (zh)	2020-06-02	2023-08-01	当康生物技术有限责任公司	抗cd93构建体及其用途
US20230235075A1 (en)	2020-06-02	2023-07-27	Dynamicure Biotechnology Llc	Anti-cd93 constructs and uses thereof
JP2023527918A (ja)	2020-06-08	2023-06-30	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｈｂｖ抗体及び使用方法
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
MX2022015877A (es)	2020-06-16	2023-01-24	Genentech Inc	Metodos y composiciones para tratar cancer de mama triple negativo.
MX2022015881A (es)	2020-06-18	2023-01-24	Genentech Inc	Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
CN115768478A (zh)	2020-06-19	2023-03-07	中外制药株式会社	用于和血管新生抑制剂组合使用的抗t细胞抗原结合分子
CN115734971A (zh)	2020-06-22	2023-03-03	信达生物制药(苏州)有限公司	抗ang-2抗体及其用途
AU2021297856A1 (en)	2020-06-22	2023-02-02	Innovent Biologics (Suzhou) Co., Ltd.	Anti-CD73 antibody and use thereof
US20230235040A1 (en)	2020-06-22	2023-07-27	Almirall, S.A.	Anti-il-36 antibodies and methods of use thereof
JP2023533217A (ja)	2020-06-24	2023-08-02	ジェネンテック，インコーポレイテッド	アポトーシス耐性細胞株
CA3183557A1 (en)	2020-06-24	2021-12-30	Bioverativ Therapeutics Inc.	Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
WO2022006153A1 (en)	2020-06-29	2022-01-06	Resolve Therapeutics, Llc	Treatment of sjogren's syndrome with nuclease fusion proteins
MX2023000339A (es)	2020-07-10	2023-02-09	Hoffmann La Roche	Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas.
CN116406377A (zh)	2020-07-17	2023-07-07	基因泰克公司	抗notch2抗体及其使用方法
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
EP4188550A1 (en)	2020-07-29	2023-06-07	Dynamicure Biotechnology LLC	Anti-cd93 constructs and uses thereof
EP4189121A1 (en)	2020-08-03	2023-06-07	Genentech, Inc.	Diagnostic and therapeutic methods for lymphoma
PH12023500005A1 (en)	2020-08-25	2023-08-14	Gilead Sciences Inc	Multi-specific antigen binding molecules targeting hiv and methods of use
EP4204448A2 (en)	2020-08-27	2023-07-05	cureab GmbH	Anti-golph2 antibodies for macrophage and dendritic cell differentiation
JP2023539201A (ja)	2020-08-28	2023-09-13	ジェネンテック，インコーポレイテッド	宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
EP4208201A1 (en)	2020-09-04	2023-07-12	F. Hoffmann-La Roche AG	Antibody that binds to vegf-a and ang2 and methods of use
PE20231575A1 (es)	2020-09-14	2023-10-04	Ichnos Sciences SA	Anticuerpos que se unen a il1rap y usos de estos
EP4213877A1 (en)	2020-09-17	2023-07-26	Genentech, Inc.	Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
CN116648463A (zh)	2020-09-18	2023-08-25	伊克诺斯科学公司	Cd47-cd38双特异性抗体
EP4217389A4 (en)	2020-09-28	2025-03-19	Angitia Incorporated Limited	ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF
TWI836278B (zh)	2020-10-05	2024-03-21	美商建南德克公司	用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
WO2022076606A1 (en)	2020-10-06	2022-04-14	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en)	2020-10-06	2023-08-16	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202233671A (zh)	2020-10-20	2022-09-01	美商建南德克公司	Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
AU2021363766A1 (en)	2020-10-22	2023-06-15	Janssen Biotech, Inc.	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
EP4240492A2 (en)	2020-11-04	2023-09-13	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CA3196076A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
IL302217A (en)	2020-11-04	2023-06-01	Genentech Inc	Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
CN117946281A (zh)	2020-11-19	2024-04-30	舒泰神（北京）生物制药股份有限公司	长效神经生长因子多肽及其用途
KR20230113581A (ko)	2020-11-25	2023-07-31	실리오 디벨럽먼트, 인크.	종양 특이적 절단성 링커
AU2021391054A1 (en)	2020-12-02	2023-06-22	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
US20240131064A1 (en)	2020-12-11	2024-04-25	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en)	2020-12-17	2022-06-23	Iovance Biotherapeutics, Inc.	Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en)	2020-12-17	2024-04-18	Iovance Biotherapeutics, Inc.	Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
CA3203257A1 (en)	2020-12-23	2022-06-30	Li Li	Anti-b7-h3 antibody and uses thereof
JP2024501845A (ja)	2020-12-31	2024-01-16	アイオバンスバイオセラピューティクス，インコーポレイテッド	腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
JP2024504931A (ja)	2021-01-12	2024-02-02	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
US20240173442A1 (en)	2021-01-13	2024-05-30	Hoffmann-La Roche Inc.	Combination therapy
TW202241508A (zh)	2021-01-29	2022-11-01	美商艾歐凡斯生物治療公司	細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
MX2023009100A (es)	2021-02-03	2023-09-25	Mozart Therapeutics Inc	Agentes aglutinantes y métodos para usar los mismos.
EP4288458A1 (en)	2021-02-03	2023-12-13	Genentech, Inc.	Multispecific binding protein degrader platform and methods of use
US20240026019A1 (en)	2021-02-04	2024-01-25	Innovent Biologics (Suzhou) Co., Ltd.	Anti-tnfr2 antibody and use thereof
JP7559257B2 (ja)	2021-02-17	2024-10-01	プロメテウスバイオサイエンシーズ，インク．	抗ｃｄ３０ｌ抗体およびその使用
US20220340662A1 (en)	2021-03-01	2022-10-27	Xilio Development, Inc.	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301467A1 (en)	2021-03-01	2024-01-10	Xilio Development, Inc.	Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CN117279506A (zh)	2021-03-05	2023-12-22	艾欧凡斯生物治疗公司	肿瘤储存及细胞培养组合物
WO2022187863A1 (en)	2021-03-05	2022-09-09	Dynamicure Biotechnology Llc	Anti-vista constructs and uses thereof
US20240392004A1 (en)	2021-03-10	2024-11-28	Immunowake Inc.	Immunomodulatory molecules and uses thereof
JP2024512377A (ja)	2021-03-12	2024-03-19	ジェネンテック，インコーポレイテッド	抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
WO2022198192A1 (en)	2021-03-15	2022-09-22	Genentech, Inc.	Compositions and methods of treating lupus nephritis
EP4308242A1 (en)	2021-03-17	2024-01-24	Molecular Templates, Inc.	Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US12036286B2 (en)	2021-03-18	2024-07-16	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
US20240191191A1 (en)	2021-03-19	2024-06-13	Iovance Biotherapeutics, Inc.	Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204155A1 (en)	2021-03-23	2022-09-29	Iovance Biotherapeutics, Inc.	Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3213163A1 (en)	2021-03-25	2022-09-29	Iovance Biotherapeutics, Inc.	Methods and compositions for t-cell coculture potency assays and use with cell therapy products
CN117616041A (zh)	2021-03-25	2024-02-27	当康生物技术有限责任公司	抗-igfbp7构建体及其用途
EP4314059A1 (en)	2021-03-26	2024-02-07	Janssen Biotech, Inc.	Humanized antibodies against paired helical filament tau and uses thereof
CA3215049A1 (en)	2021-04-10	2022-10-13	Baiteng ZHAO	Folr1 binding agents, conjugates thereof and methods of using the same
AU2022263418A1 (en)	2021-04-19	2023-10-26	Iovance Biotherapeutics, Inc.	Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4326855A1 (en)	2021-04-19	2024-02-28	Genentech, Inc.	Modified mammalian cells
EP4326768A1 (en)	2021-04-23	2024-02-28	Profoundbio Us Co.	Anti-cd70 antibodies, conjugates thereof and methods of using the same
AU2022270170A1 (en)	2021-05-07	2023-09-21	Surface Oncology, LLC	Anti-il-27 antibodies and uses thereof
EP4333869A1 (en)	2021-05-07	2024-03-13	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
KR20240007184A (ko)	2021-05-12	2024-01-16	제넨테크, 인크.	미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
AU2022273541A1 (en)	2021-05-14	2023-11-30	Genentech, Inc.	Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
JP2024518545A (ja)	2021-05-14	2024-05-01	ジェネンテック，インコーポレイテッド	Ｔｒｅｍ２のアゴニスト
US20240269180A1 (en)	2021-05-17	2024-08-15	Iovance Biotherapeutics, Inc.	Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022246259A1 (en)	2021-05-21	2022-11-24	Genentech, Inc.	Modified cells for the production of a recombinant product of interest
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
BR112023025863A2 (pt)	2021-06-11	2024-03-05	Genentech Inc	Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2
WO2022266660A1 (en)	2021-06-17	2022-12-22	Amberstone Biosciences, Inc.	Anti-cd3 constructs and uses thereof
CA3221833A1 (en)	2021-06-25	2022-12-29	Chugai Seiyaku Kabushiki Kaisha	Anti-ctla-4 antibody
MX2023014453A (es)	2021-06-25	2024-01-31	Chugai Pharmaceutical Co Ltd	Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
TW202320857A (zh)	2021-07-06	2023-06-01	美商普方生物製藥美國公司	連接子、藥物連接子及其結合物及其使用方法
US20250011448A1 (en)	2021-07-08	2025-01-09	Staidson Biopharma Inc.	Antibodies specifically recognizing tnfr2 and uses thereof
JP2024530402A (ja)	2021-07-12	2024-08-21	ジェネンテック，インコーポレイテッド	抗体－リパーゼ結合を減少させるための構造
EP4370553A1 (en)	2021-07-14	2024-05-22	Genentech, Inc.	Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
KR20240058075A (ko)	2021-07-14	2024-05-03	스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드	Cd40을 특이적으로 식별하는 항체 및 이의 응용
JP2024526880A (ja)	2021-07-22	2024-07-19	ジェネンテック，インコーポレイテッド	脳標的化組成物及びその使用方法
EP4373270A2 (en)	2021-07-22	2024-05-29	Iovance Biotherapeutics, Inc.	Method for cryopreservation of solid tumor fragments
WO2023001884A1 (en)	2021-07-22	2023-01-26	F. Hoffmann-La Roche Ag	Heterodimeric fc domain antibodies
EP4377338A2 (en)	2021-07-27	2024-06-05	Novab, Inc.	Engineered vlrb antibodies with immune effector functions
WO2023009716A1 (en)	2021-07-28	2023-02-02	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022318161A1 (en)	2021-07-29	2024-02-08	Centre Leon Berard	HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
WO2023011338A1 (zh)	2021-08-02	2023-02-09	信达生物制药(苏州)有限公司	抗CD79b×CD3双特异性抗体及其用途
JP2024528217A (ja)	2021-08-03	2024-07-26	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗体および使用方法
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2024534004A (ja)	2021-08-13	2024-09-18	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体のための投与量
WO2023021055A1 (en)	2021-08-19	2023-02-23	F. Hoffmann-La Roche Ag	Multivalent anti-variant fc-region antibodies and methods of use
IL310382A (en)	2021-08-27	2024-03-01	Genentech Inc	Methods for treating tau pathologies
WO2023034750A1 (en)	2021-08-30	2023-03-09	Genentech, Inc.	Anti-polyubiquitin multispecific antibodies
CA3231018A1 (en)	2021-09-09	2023-03-16	Iovance Biotherapeutics, Inc.	Processes for generating til products using pd-1 talen knockdown
CA3232700A1 (en)	2021-09-24	2023-03-30	Rafael CUBAS	Expansion processes and agents for tumor infiltrating lymphocytes
WO2023053282A1 (ja)	2021-09-29	2023-04-06	中外製薬株式会社	がんの治療に用いるための細胞傷害誘導治療剤
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN116064598B (zh)	2021-10-08	2024-03-12	苏州艾博生物科技有限公司	冠状病毒的核酸疫苗
WO2023076876A1 (en)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation of immune responses to viral vectors
CA3235824A1 (en)	2021-10-27	2023-05-04	Frederick G. Vogt	Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4426748A4 (en)	2021-11-05	2025-11-26	Mab Biotec Inc	Monoclonal antibodies against carcinomebryonal antigens and their uses
CA3237410A1 (en)	2021-11-10	2023-05-19	Friedrich Graf Finck VON FINCKENSTEIN	Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
CA3235206A1 (en)	2021-11-16	2023-05-25	Davide BASCO	Novel molecules for therapy and diagnosis
EP4445911A4 (en)	2021-12-06	2025-10-22	Beijing Solobio Genetechnology Co Ltd	BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
CA3237618A1 (en)	2021-12-15	2023-06-22	Genentech, Inc.	Stabilized il-18 polypeptides and uses thereof
WO2023109901A1 (en)	2021-12-17	2023-06-22	Shanghai Henlius Biotech, Inc.	Anti-ox40 antibodies and methods of use
EP4448578A4 (en)	2021-12-17	2026-02-18	Shanghai Henlius Biotech Inc	ANTI-OX40 ANTIBODIES, MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
WO2023141445A1 (en)	2022-01-19	2023-07-27	Genentech, Inc.	Anti-notch2 antibodies and conjugates and methods of use
JP2025504908A (ja)	2022-01-28	2025-02-19	アイオバンスバイオセラピューティクス，インコーポレイテッド	サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
JP2025503987A (ja)	2022-01-28	2025-02-06	アイオバンスバイオセラピューティクス，インコーポレイテッド	ペイロードを発現するように操作された腫瘍浸潤リンパ球
JP2025508389A (ja)	2022-02-10	2025-03-26	サインエイバイオソリューションズゲーエムベーハー	慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用
EP4227321A1 (en)	2022-02-10	2023-08-16	AVA Lifescience GmbH	Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
US20250243260A1 (en)	2022-03-07	2025-07-31	Alpine Immune Sciences, Inc.	Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
CA3254615A1 (en)	2022-03-11	2023-09-14	Janssen Pharmaceutica Nv	MULTISPECIFIC ANTIBODIES AND THEIR USES
IL315544A (en)	2022-03-11	2024-11-01	Janssen Pharmaceutica Nv	Multispecific antibodies and their uses
WO2023170291A1 (en)	2022-03-11	2023-09-14	Janssen Pharmaceutica Nv	Multispecific antibodies and uses thereof
CN119562970A (zh)	2022-03-18	2025-03-04	进化免疫治疗公司	双特异性抗体融合分子及其使用方法
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
WO2023191816A1 (en)	2022-04-01	2023-10-05	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
EP4504220A1 (en)	2022-04-06	2025-02-12	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2025512342A (ja)	2022-04-13	2025-04-17	ジェネンテック，インコーポレイテッド	治療用タンパク質の医薬組成物および使用方法
CA3248034A1 (en)	2022-04-15	2023-10-19	Iovance Biotherapeutics, Inc.	METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
CN119137157A (zh)	2022-05-03	2024-12-13	基因泰克公司	抗Ly6E抗体、免疫缀合物及其用途
US20240228650A9 (en)	2022-05-06	2024-07-11	Ichnos Sciences SA	CD3/BCMA/CD38 Trispecific Antibodies
EP4524158A4 (en)	2022-05-09	2025-12-17	Staidson Beijing Biopharmaceuticals Co Ltd	Antibody that specifically recognizes gdf15 and use thereof
CA3251533A1 (en)	2022-05-10	2023-11-16	Iovance Biotherapeutics, Inc.	TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
AR129268A1 (es)	2022-05-11	2024-08-07	Hoffmann La Roche	Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20250282874A1 (en)	2022-05-17	2025-09-11	Suzhou Transcenta Therapeutics Co., Ltd.	Bifunctional protein, and preparation thereof and use thereof
EP4279092A1 (en)	2022-05-17	2023-11-22	Bayer AG	Radiopharmaceutical complexes targeting prostate-specific membrane antigen
KR20250011935A (ko)	2022-05-17	2025-01-22	바이엘 악티엔게젤샤프트	전립선-특이적 막 항원을 표적화하는 방사성제약 복합체 및 그의 조합물
AU2023276940A1 (en)	2022-05-26	2024-12-12	Pfizer Inc.	Anti-tnfr2 antibodies and methods of use thereof
CN119278212A (zh)	2022-05-31	2025-01-07	辉瑞大药厂	抗bmp9抗体及其使用方法
WO2023235699A1 (en)	2022-05-31	2023-12-07	Jounce Therapeutics, Inc.	Antibodies to lilrb4 and uses thereof
CN119856056A (zh)	2022-06-07	2025-04-18	基因泰克公司	用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法
CA3258639A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Multispecific molecules to modulate T lymphocyte activity, and their uses
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
WO2023239803A1 (en)	2022-06-08	2023-12-14	Angiex, Inc.	Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
EP4551681A1 (en)	2022-07-06	2025-05-14	Iovance Biotherapeutics, Inc.	Devices and processes for automated production of tumor infiltrating lymphocytes
CA3261147A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
US20260035464A1 (en)	2022-07-19	2026-02-05	Staidson Biopharma Inc.	Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
CN119604530A (zh)	2022-07-19	2025-03-11	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
EP4558528A1 (en)	2022-07-22	2025-05-28	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
EP4565683A1 (en)	2022-08-01	2025-06-11	Iovance Biotherapeutics, Inc.	Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024030956A2 (en)	2022-08-03	2024-02-08	Mozart Therapeutics, Inc.	Cd39-specific binding agents and methods of using the same
CN120603847A (zh)	2022-08-03	2025-09-05	辉瑞公司	抗il27r抗体及其使用方法
CA3263779A1 (en)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	CD98 LINKAGE CONSTRUCTIONS FOR THE TREATMENT OF BRAIN TUMORS
CN120077064A (zh)	2022-08-05	2025-05-30	詹森生物科技公司	用于治疗脑肿瘤的转铁蛋白受体结合蛋白
IL318702A (en)	2022-08-19	2025-03-01	Evive Biotechnology Shanghai Ltd	Compositions containing G-CSF and their uses
TW202423979A (zh)	2022-08-22	2024-06-16	美商雅博得樂醫療公司	Dll3結合分子及其用途
KR20250054799A (ko)	2022-08-29	2025-04-23	다이이찌 산쿄 가부시키가이샤	변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
JP2025529210A (ja)	2022-09-01	2025-09-04	ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド	アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CN120153254A (zh)	2022-09-01	2025-06-13	基因泰克公司	膀胱癌的治疗和诊断方法
CN120077071A (zh)	2022-09-07	2025-05-30	当康生物技术有限责任公司	抗vista构建体及其用途
US12054552B2 (en)	2022-09-21	2024-08-06	Sanofi Biotechnology	Humanized anti-IL-1R3 antibody and methods of use
WO2024067344A1 (zh)	2022-09-27	2024-04-04	舒泰神（北京）生物制药股份有限公司	特异性识别light的抗体及其应用
CN120344256A (zh)	2022-10-04	2025-07-18	高山免疫科学股份有限公司	突变的taci-fc融合蛋白用于在治疗自身抗体介导的疾病中的用途
IL319943A (en)	2022-10-07	2025-05-01	Genentech Inc	Methods for treating cancer with anti-C motif chemokine receptor 8 (CCR8) antibodies
EP4605752A1 (en)	2022-10-17	2025-08-27	Institut Gustave Roussy	Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
EP4606886A1 (en)	2022-10-20	2025-08-27	Beijing SoloBio Genetechnology Company Ltd.	Antibody combination specifically binding to trail or fasl, and bispecific antibody
EP4608859A1 (en)	2022-10-25	2025-09-03	Ablynx N.V.	Glycoengineered fc variant polypeptides with enhanced effector function
TW202426505A (zh)	2022-10-25	2024-07-01	美商建南德克公司	癌症之治療及診斷方法
WO2024094741A1 (en)	2022-11-03	2024-05-10	F. Hoffmann-La Roche Ag	Combination therapy with anti-cd19/anti-cd28 bispecific antibody
AU2023373363A1 (en)	2022-11-04	2025-05-08	Gilead Sciences, Inc.	Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024098024A1 (en)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
JP2025537155A (ja)	2022-11-04	2025-11-14	アイオバンスバイオセラピューティクス，インコーポレイテッド	Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
AU2023375342A1 (en)	2022-11-08	2025-04-24	F. Hoffmann-La Roche Ag	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
KR20250106304A (ko)	2022-11-17	2025-07-09	사노피	Ceacam5 항체-약물 접합체 및 이의 사용 방법
KR20250122544A (ko)	2022-11-21	2025-08-13	이오반스 바이오테라퓨틱스, 인크.	종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
JP2025539712A (ja)	2022-11-21	2025-12-09	アイオバンスバイオセラピューティクス，インコーポレイテッド	遺伝子編集されたｔ細胞の増殖能を評価するための方法
IL320881A (en)	2022-11-25	2025-07-01	Chugai Pharmaceutical Co Ltd	Method for producing protein
EP4382120A1 (en)	2022-12-05	2024-06-12	Institut Regional du Cancer de Montpellier	Anti-slc1a4 monoclonal antibodies and uses thereof
WO2024121311A1 (en)	2022-12-07	2024-06-13	Ichnos Sciences SA	Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
WO2024120516A1 (zh)	2022-12-08	2024-06-13	南京诺唯赞生物科技股份有限公司	特异性结合rsv的抗体
WO2024126833A1 (en)	2022-12-16	2024-06-20	Ichnos Sciences SA	Cd47-il1rap bispecific antibodies
JP2025542327A (ja)	2022-12-23	2025-12-25	チマゲン・バイオサイエンシズ，リミテッド	新規抗ｇｐｒｃ５ｄ抗体
CN120476149A (zh)	2022-12-23	2025-08-12	成都恩沐生物科技有限公司	靶向gprc5d的多特异性多肽复合物
WO2024145398A1 (en)	2022-12-27	2024-07-04	Yale University	Antibody drug conjugates
WO2024151885A1 (en)	2023-01-13	2024-07-18	Iovance Biotherapeutics, Inc.	Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
TW202432607A (zh)	2023-01-18	2024-08-16	美商建南德克公司	多特異性抗體及其用途
EP4655007A1 (en)	2023-01-23	2025-12-03	Yale University	Antibody oligonucleotide conjugates
EP4665392A2 (en)	2023-02-14	2025-12-24	Evolveimmune Therapeutics, Inc.	Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
AU2024221136A1 (en)	2023-02-17	2025-10-02	Ablynx N.V.	Polypeptides binding to the neonatal fc receptor
WO2024191785A1 (en)	2023-03-10	2024-09-19	Genentech, Inc.	Fusions with proteases and uses thereof
WO2024197302A1 (en)	2023-03-23	2024-09-26	Yale University	Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
TW202446789A (zh)	2023-03-31	2024-12-01	美商建南德克公司	抗αｖβ８整合素抗體及使用方法
WO2024211796A1 (en)	2023-04-07	2024-10-10	Diagonal Therapeutics Inc.	Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024212827A1 (en)	2023-04-12	2024-10-17	Shanghai Kangabio Co., Limited	Multifunctional molecules comprising masked interleukin 12 and methods of use
CN121263210A (zh)	2023-04-17	2026-01-02	沛科生物公司	抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2024218260A1 (en)	2023-04-18	2024-10-24	Institut Gustave Roussy	Detecting tumor-associated-macrophages in pancreatic cancer
WO2024218650A1 (en)	2023-04-19	2024-10-24	Pfizer Inc.	Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2024226829A2 (en)	2023-04-26	2024-10-31	Yale University	Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
AU2024270495A1 (en)	2023-05-05	2025-10-09	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en)	2023-05-08	2025-10-23	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
KR20260008790A (ko)	2023-05-10	2026-01-16	제넨테크, 인크.	암 치료 방법 및 조성물
TW202509065A (zh)	2023-05-16	2025-03-01	瑞士商赫孚孟拉羅股份公司	經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
AU2024275646A1 (en)	2023-05-24	2025-11-13	Mozart Therapeutics, Inc.	Cd8-specific binding proteins and methods of using the same
CN121285742A (zh)	2023-06-08	2026-01-06	基因泰克公司	用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
WO2024251199A1 (zh)	2023-06-09	2024-12-12	舒泰神（北京）生物制药股份有限公司	特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
WO2024255794A1 (zh)	2023-06-16	2024-12-19	舒泰神（北京）生物制药股份有限公司	特异性识别因子XIIa的抗体及其应用
WO2024263761A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Antibodies and uses thereof
CN121443309A (zh)	2023-06-22	2026-01-30	基因泰克公司	多发性骨髓瘤的治疗
WO2025007037A1 (en)	2023-06-28	2025-01-02	Dragonfly Therapeutics, Inc.	Variant il-2 proteins
AU2024309736A1 (en)	2023-06-30	2026-01-15	Evive Biotechnology (Shanghai) Ltd	G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
AU2024296516A1 (en)	2023-07-13	2026-01-22	Iovance Biotherapeutics, Inc.	Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
AU2024292473A1 (en)	2023-07-19	2026-01-29	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025022280A1 (en)	2023-07-21	2025-01-30	Astrazeneca Ab	Treatment of neurodegenerative diseases
WO2025021790A2 (en)	2023-07-24	2025-01-30	F. Hoffmann-La Roche Ag	Multispecific antibodies
WO2025027003A1 (en)	2023-07-31	2025-02-06	Sanofi	Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Anti-a-beta protein antibodies, methods and uses thereof
WO2025041077A1 (en)	2023-08-23	2025-02-27	Sanofi	Ctla-4-based lysosomal degraders and uses thereof
WO2025049905A1 (en)	2023-09-01	2025-03-06	Gennao Bio, Inc.	Dnase co-expression in host cells
WO2025045250A1 (en)	2023-09-03	2025-03-06	Kira Pharmaceuticals (Us) Llc	Anti-human factor d antibody constructs and uses thereof
WO2025054500A2 (en)	2023-09-08	2025-03-13	Mlab Biosciences, Inc.	Bifunctional proteins and uses thereof
WO2025059037A1 (en)	2023-09-11	2025-03-20	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064890A1 (en)	2023-09-20	2025-03-27	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en)	2023-09-20	2025-03-27	Evolveimmune Therapeutics, Inc.	Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
AR133909A1 (es)	2023-09-25	2025-11-12	Hoffmann La Roche	ANTICUERPO QUE SE UNE A C3bBb
TW202535954A (zh)	2023-09-26	2025-09-16	丹麥商珍美寶股份有限公司	Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
TW202517674A (zh)	2023-10-19	2025-05-01	德商拜耳廠股份有限公司	抗gpc3抗體及其放射性結合物
WO2025101484A1 (en)	2023-11-06	2025-05-15	Iovance Biotherapeutics, Inc.	Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
EP4552657A1 (en)	2023-11-07	2025-05-14	Bayer Aktiengesellschaft	Radiopharmaceutical complexes and combinations
WO2025099120A1 (en)	2023-11-09	2025-05-15	F. Hoffmann-La Roche Ag	Multispecific antibodies with conditional activity
US20250154287A1 (en)	2023-11-10	2025-05-15	Pfizer Inc.	ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
US20250163168A1 (en)	2023-11-17	2025-05-22	Pfizer Inc.	Novel antibodies and antibody conjugates for the treatment of metabolic disorders
TW202535955A (zh)	2023-11-27	2025-09-16	丹麥商珍美寶股份有限公司	用於ｐｔｋ７檢測之抗體及方法
WO2025132503A1 (en)	2023-12-20	2025-06-26	F. Hoffmann-La Roche Ag	Antibodies binding to ceacam5
WO2025137410A1 (en)	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025137523A2 (en)	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025133290A1 (en)	2023-12-21	2025-06-26	Temper Bio	Protein for immune regulation
WO2025133042A2 (en)	2023-12-22	2025-06-26	F. Hoffmann-La Roche Ag	Activatable fusion proteins and methods of use
WO2025147696A1 (en)	2024-01-05	2025-07-10	Resolve Therapeutics, Llc	Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025149661A1 (en)	2024-01-10	2025-07-17	Genmab A/S	Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149633A1 (en)	2024-01-12	2025-07-17	Laigo Bio B.V.	Bispecific antigen binding proteins
WO2025171182A1 (en)	2024-02-08	2025-08-14	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025172924A1 (en)	2024-02-15	2025-08-21	Janssen Biotech, Inc.	Anti-transferrin receptor compositions and methods thereof
WO2025181219A1 (en)	2024-02-29	2025-09-04	Genmab A/S	Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250295801A1 (en)	2024-03-21	2025-09-25	Seagen Inc.	Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025215060A1 (en)	2024-04-11	2025-10-16	F. Hoffmann-La Roche Ag	Antibodies that specifically bind modified oligonucleotides
WO2025222129A2 (en)	2024-04-19	2025-10-23	Mozart Therapeutics, Inc.	Engineered cytokines and targeted cytokine delivery
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
WO2025226808A1 (en)	2024-04-24	2025-10-30	Genentech, Inc.	Compositions and methods of treating lupus nephritis
EP4644413A1 (en)	2024-05-03	2025-11-05	Genmab B.V.	Binding agents having altered fc-mediated effector functions
WO2025245176A1 (en)	2024-05-22	2025-11-27	Bristol-Myers Squibb Company	Multispecific antibody constructs
WO2025248500A1 (en)	2024-05-31	2025-12-04	Janssen Biotech, Inc.	Antibody drug conjugates that target enpp3
WO2025250969A1 (en)	2024-05-31	2025-12-04	Vertex Pharmaceuticals Incorporated	Anti-cd74 antibodies, conjugates and uses thereof
WO2025255353A1 (en)	2024-06-06	2025-12-11	Apogee Therapeutics, Inc.	Dosage and administration of an anti-ox40l antibody
WO2025257715A1 (en)	2024-06-12	2025-12-18	Seagen Inc.	Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
WO2025262564A1 (en)	2024-06-17	2025-12-26	Pfizer Inc.	Use of anti-cxcr5 antibodies
WO2025264972A1 (en)	2024-06-21	2025-12-26	Apogee Therapeutics, Inc.	Antibodies that bind il-4r alpha and antibodies that bind
WO2025264960A1 (en)	2024-06-21	2025-12-26	Apogee Therapeutics, Inc.	Antibodies that bind il-13 and antibodies that bind ox40l
WO2026006784A1 (en)	2024-06-28	2026-01-02	Iovance Biotherapeutics, Inc.	Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026008525A1 (en)	2024-07-01	2026-01-08	Bayer Aktiengesellschaft	Stable radionuclide-containing formulations
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0307434B2 (en) *	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
AU691811B2 (en) *	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5834597A (en) *	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1998023289A1 (en) *	1996-11-27	1998-06-04	The General Hospital Corporation	MODULATION OF IgG BINDING TO FcRn

1999
- 1999-03-31 DK DK99915101T patent/DK1068241T3/da active
- 1999-03-31 CA CA2323757A patent/CA2323757C/en not_active Expired - Lifetime
- 1999-03-31 AU AU33699/99A patent/AU3369999A/en not_active Abandoned
- 1999-03-31 IL IL13860899A patent/IL138608A0/xx unknown
- 1999-03-31 DE DE69937291T patent/DE69937291T2/de not_active Expired - Lifetime
- 1999-03-31 WO PCT/US1999/006858 patent/WO1999051642A1/en not_active Ceased
- 1999-03-31 JP JP2000542363A patent/JP2002510481A/ja active Pending
- 1999-03-31 ES ES06000719.2T patent/ES2532910T3/es not_active Expired - Lifetime
- 1999-03-31 PT PT99915101T patent/PT1068241E/pt unknown
- 1999-03-31 AT AT99915101T patent/ATE375365T1/de active
- 1999-03-31 ES ES99915101T patent/ES2292236T3/es not_active Expired - Lifetime
- 1999-03-31 EP EP99915101A patent/EP1068241B1/en not_active Expired - Lifetime
2007
- 2007-12-19 CY CY20071101607T patent/CY1107099T1/el unknown

Also Published As

Publication number	Publication date
CY1107099T1 (el)	2012-10-24
ES2292236T3 (es)	2008-03-01
DE69937291T2 (de)	2008-07-10
WO1999051642A1 (en)	1999-10-14
DE69937291D1 (de)	2007-11-22
EP1068241B1 (en)	2007-10-10
ES2532910T3 (es)	2015-04-01
CA2323757A1 (en)	1999-10-14
AU3369999A (en)	1999-10-25
HK1095337A1 (en)	2007-05-04
EP1068241A1 (en)	2001-01-17
CA2323757C (en)	2011-08-02
IL138608A0 (en)	2001-10-31
ATE375365T1 (de)	2007-10-15
PT1068241E (pt)	2007-11-19
JP2002510481A (ja)	2002-04-09

Publication	Publication Date	Title
DK1068241T3 (da)	2008-02-04	Antistofvarianter og fragmenter deraf
DE69931507D1 (de)	2006-06-29	Interferon-beta fusionsproteine und deren verwendungen
NO953901L (no)	1996-01-04	Rekombinante alfavirus-vektorer
BR9504791B1 (pt)	2010-10-05	composto de polipeptìdeo e composição farmacêutica.
TR199600357A2 (tr)	1996-11-21	Rekombinant simanlik (Ob) proteinleri.
WO1998033509A3 (en)	1999-03-11	Useful properties of human lactoferrin and variants thereof
EP1572718A3 (en)	2005-07-28	Alpha nu beta 3 integrin-binding polypeptide monobodies and their use
DK0489116T3 (da)	1994-05-02	Fusionsproteiner omfattende GM-CSF og IL-3
ATE339507T1 (de)	2006-10-15	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
FI943389L (fi)	1995-01-16	Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
AU8812498A (en)	1999-02-10	Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO1997020933A3 (en)	1997-10-02	Mutational variants of mammalian ob gene proteins
BR0211186A (pt)	2007-01-30	peptìdeos e uso dos mesmos no escurecimento da pele
AU2507895A (en)	1996-02-01	Protein guarantor composition and its application
FI956178A0 (fi)	1995-12-21	Varsibromelaiiniproteaasin lääkekäyttö
PT723552E (pt)	2003-02-28	Oligopeptidos derivados de fragmentos de proteina reactiva c
EP1746107A3 (en)	2012-01-18	Antibody variants and fragments thereof
AU3577589A (en)	1990-11-05	Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
IT1264129B1 (it)	1996-09-16	Peptidi ad attivita' immunomodulatoria derivati da frammenti di leucochinina
ITRM940711A0 (it)	1994-11-04	"circuito tampone e relativo procedimento di funzionamento"
BR9507063A (pt)	1997-09-02	Peptídeo derivado de substituição de peptídeo e composição farmacêuticas
FR2747681B1 (fr)	1998-06-19	Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
ITMI932544A0 (it)	1993-12-03	Composizioni farmaceutiche e/o dermocosmetologiche e cosmetiche contenenti colostro bovino.
AU6981794A (en)	1995-01-03	Protein which catalyses peptide refolding and uses thereof
AU3975693A (en)	1993-11-08	Recombinant active forms of ECEF, proteins that associate therewith, and uses thereof